8387Accesses
809Citations
20 Altmetric
1Mention
Abstract
The purpose of this expert review is to discuss the impact of nanotechnology in the treatment of the major health threats including cancer, infections, metabolic diseases, autoimmune diseases, and inflammations. Indeed, during the past 30 years, the explosive growth of nanotechnology has burst into challenging innovations in pharmacology, the main input being the ability to perform temporal and spatial site-specific delivery. This has led to some marketed compounds through the last decade. Although the introduction of nanotechnology obviously permitted to step over numerous milestones toward the development of the “magic bullet” proposed a century ago by the immunologist Paul Ehrlich, there are, however, unresolved delivery problems to be still addressed. These scientific and technological locks are discussed along this review together with an analysis of the current situation concerning the industrial development.
This is a preview of subscription content,log in via an institution to check access.
Access this article
Subscribe and save
- Starting from 10 chapters or articles per month
- Access and download chapters and articles from more than 300k books and 2,500 journals
- Cancel anytime
Buy Now
Price includes VAT (Japan)
Instant access to the full article PDF.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, books and news in related subjects, suggested using machine learning.References
G. Gregoriadis E. J. Wills C. P. Swain A. S. Tavill (1974)ArticleTitleDrug carrier potential of liposomes in cancer chemotherapyLancet1 1313–1316OccurrenceHandle4134296OccurrenceHandle1:STN:280:DyaE2c3lt12lsg%3D%3DOccurrenceHandle10.1016/S0140-6736(74)90682-5
C. Hu D. G. Rhodes (2000)ArticleTitleProniosomes: a novel drug carrier preparationInt. J. Pharm.206 110–122OccurrenceHandle11202988OccurrenceHandle1:STN:280:DC%2BD3M%2FjtVKqsA%3D%3DOccurrenceHandle10.1016/S0378-5173(00)00513-5
K. K. Jain (2005)ArticleTitleThe role of nanobiotechnology in drug discoveryDrug Discov. Today10 1435–1442OccurrenceHandle16243263OccurrenceHandle1:CAS:528:DC%2BD2MXhtFers7rLOccurrenceHandle10.1016/S1359-6446(05)03573-7
J. K. Vasir M. K. Maram V. D. Labhasetwar (2005)ArticleTitleNanosystems in drug targeting: opportunities and challengesCurr. Nanosci.1 47–67OccurrenceHandle1:CAS:528:DC%2BD2MXit1aktb4%3DOccurrenceHandle10.2174/1573413052953110
A. Bianco J. Hoebeke S. Godefroy O. Chaloin D. Pantarotto J. P. Briand S. Muller M. Prati C. D. Partidos (2005)ArticleTitleCationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory propertiesJ. Am. Chem. Soc.127 58–59OccurrenceHandle15631447OccurrenceHandle1:CAS:528:DC%2BD2cXhtVyltrvOOccurrenceHandle10.1021/ja044293y
A. Bianco K. Costarelos M. Prato (2005)ArticleTitleApplications of carbon nanotubes in drug deliveryCurr. Opin. Chem. Biol.9 674–679OccurrenceHandle16233988OccurrenceHandle1:CAS:528:DC%2BD2MXht1aqu7fJOccurrenceHandle10.1016/j.cbpa.2005.10.005
N. Venkatesan J. Yoshimitsu Y. Ito N. Shibata K. Takada (2005)ArticleTitleLiquid filled nanoparticles as a drug delivery tool for protein therapeuticsBiomaterials26 7154–7163OccurrenceHandle15967493OccurrenceHandle1:CAS:528:DC%2BD2MXmvFCqu7o%3DOccurrenceHandle10.1016/j.biomaterials.2005.05.012
M. J. Alonso (2004)ArticleTitleNanomedicine for overcoming biological barriersBiomed. Pharmacother.58 168–172OccurrenceHandle15082339OccurrenceHandle10.1016/j.biopha.2004.01.007OccurrenceHandle1:CAS:528:DC%2BD2cXjtV2gsLs%3D
R. Sykes (2000)ArticleTitleTowards the magic bulletInt. J. Antimicrob. Agents14 1–12OccurrenceHandle10717495OccurrenceHandle1:CAS:528:DC%2BD3cXhslelu74%3DOccurrenceHandle10.1016/S0924-8579(99)00141-7
R. H. Muller C. Jacobs O. Kayser (2001)ArticleTitleNanosuspensions as particulate drug formulations in therapy rational for development and what we can expect for the futureAdv. Drug Deliv. Rev.47 3–19OccurrenceHandle11251242OccurrenceHandle1:CAS:528:DC%2BD3MXhvVajsr0%3DOccurrenceHandle10.1016/S0169-409X(00)00118-6
P. L. Felgner T. R. Gadek M. Holm R. Roman H. W. Chan M. Wenz J. P. Northrop G. M. Ringold M. Danielsen (1987)ArticleTitleLipofection: a highly efficient, lipid-mediated DNA-transfection procedureProc. Natl. Acad. Sci. USA84 7413–7417OccurrenceHandle2823261OccurrenceHandle1:CAS:528:DyaL1cXjtlSgug%3D%3DOccurrenceHandle10.1073/pnas.84.21.7413
J. P. Behr B. Demeneix J. P. Loeffler J. Perez-Mutul (1989)ArticleTitleEfficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNAProc. Natl. Acad. Sci. USA86 6982–6986OccurrenceHandle2780554OccurrenceHandle1:CAS:528:DyaK3cXhvF2lOccurrenceHandle10.1073/pnas.86.18.6982
A. M. Krieg (2001)ArticleTitleImmune effects and mechanisms of action of CpG motifsVaccines19 618–622OccurrenceHandle10.1016/S0264-410X(00)00249-8
A. M. Krieg (2003)ArticleTitleCpG motifs: the active ingredient in bacterial extracts?Nat. Med.9 831–835OccurrenceHandle12835699OccurrenceHandle1:CAS:528:DC%2BD3sXkvFKqtbk%3DOccurrenceHandle10.1038/nm0703-831
L. Wang R. K. Prekash C. A. Stein K. K. Koehn D. E. Ruffner (2003)ArticleTitleProgress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotidesin vivoAntisense Nucleic Acid Drug Dev.13 169–189OccurrenceHandle12954117OccurrenceHandle1:CAS:528:DC%2BD3sXmvVOmsro%3DOccurrenceHandle10.1089/108729003768247637
T. Hügle A. Cerny (2003)ArticleTitleCurrent therapy and new molecular approaches to antiviral treatment and prevention of hepatitisCrit. Rev. Med. Virol.13 361–371OccurrenceHandle10.1002/rmv.397OccurrenceHandle1:CAS:528:DC%2BD3sXpslGgtb4%3D
Z. Cui (2005)ArticleTitleDNA vaccineAdv. Genet.54 257–289OccurrenceHandle16096015OccurrenceHandle1:CAS:528:DC%2BD1cXivFWrt7c%3D
R. K. Jain (1987)ArticleTitleTransport of molecules in the tumor interstitium: a reviewCancer Res.47 3039–3051OccurrenceHandle3555767OccurrenceHandle1:CAS:528:DyaL2sXksFKlu7Y%3D
R. K. Jain (2001)ArticleTitleDelivery of molecular medicine to solid tumors: lessons fromin vivo imaging of gene expression and functionJ. Control. Release74 7–25OccurrenceHandle11489479OccurrenceHandle1:CAS:528:DC%2BD3MXlslagu7c%3DOccurrenceHandle10.1016/S0168-3659(01)00306-6
M. Links R. Brown (1999)ArticleTitleClinical relevance of the molecular mechanisms of resistance to anti-cancer drugsExpert Rev. Mol. Med.1999 1–21OccurrenceHandle14585120OccurrenceHandle1:STN:280:DC%2BD3srgvFahuw%3D%3D
R. Krishna L. D. Mayer (2000)ArticleTitleMultidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugsEur. J. Pharm. Sci.11 265–283OccurrenceHandle11033070OccurrenceHandle1:CAS:528:DC%2BD3cXntF2gtLw%3DOccurrenceHandle10.1016/S0928-0987(00)00114-7
I. Brigger C. Dubernet P. Couvreur (2002)ArticleTitleNanoparticles in cancer therapy and diagnosisAdv. Drug Deliv. Rev.54 631–651OccurrenceHandle12204596OccurrenceHandle1:CAS:528:DC%2BD38XmsVeqtrs%3DOccurrenceHandle10.1016/S0169-409X(02)00044-3
J. Kreuter U. Tauber V. Illi (1979)ArticleTitleDistribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and miceJ. Pharm. Sci.68 1443–1447OccurrenceHandle512896OccurrenceHandle1:CAS:528:DyaL3cXjtlOgsg%3D%3D
J. L. KeyserParticleDe J. H. Poupaert P. Dumont (1991)ArticleTitlePoly(diethyl methylidenemalonate) nanoparticles as a potential drug carrier: preparation, distribution and elimination after intravenous and peroral administration to miceJ. Pharm. Sci.80 67–70OccurrenceHandle2013853
B. A. Conley M. J. Egorin M. Y. Whitacre D. C. Carter E. C. Zuhowski D. A. EchoParticleVan (1993)ArticleTitlePhase I and pharmacokinetic trial of liposome-encapsulated doxorubicinCancer Chemother. Pharmacol.33 107–112OccurrenceHandle8261569OccurrenceHandle1:STN:280:DyaK2c%2FosVymtg%3D%3DOccurrenceHandle10.1007/BF00685327
N. Chiannilkulchai N. Ammoury B. Caillou J. P. Devissaguet P. Couvreur (1990)ArticleTitleHepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing miceCancer Chemother. Pharmacol.26 122–126OccurrenceHandle2189589OccurrenceHandle1:CAS:528:DyaK3cXlsFymsbo%3DOccurrenceHandle10.1007/BF02897257
A. C. VerdièreParticlede C. Dubernet F. Nemati E. Soma M. Appel J. Ferte S. Bernard F. Puisieux P. Couvreur (1997)ArticleTitleReversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of actionBr. J. Cancer76 198–205OccurrenceHandle9231919
C. E. Soma C. Dubernet G. Barratt F. Nemati M. Appel S. Benita P. Couvreur (1999)ArticleTitleAbility of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophagesPharm. Res.16 1710–1716OccurrenceHandle10571276OccurrenceHandle1:CAS:528:DyaK1MXnt1Ggs7Y%3DOccurrenceHandle10.1023/A:1018902031370
H. B. El-Serag A. C. Mason (1999)ArticleTitleRising incidence of hepatocellular carcinoma in the United StatesN. Engl. J. Med.340 745–750OccurrenceHandle10072408OccurrenceHandle1:STN:280:DyaK1M7ls1ensg%3D%3DOccurrenceHandle10.1056/NEJM199903113401001
C. L. Lai P. C. Wu G. C. Chan A. S. Lok H. J. Lin (1988)ArticleTitleDoxorubicinversus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trialCancer62 479–483OccurrenceHandle2839280OccurrenceHandle1:STN:280:DyaL1c3ntVeisg%3D%3DOccurrenceHandle10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
L. Barraud P. Merle E. Soma L. Lefrançois S. Guerret M. Chevallier C. Dubernet P. Couvreur C. Trepo L. Vitvitski (2005)ArticleTitleIncrease of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cellsin vitro andin vivoJ. Hepatol.42 736–743OccurrenceHandle15826724OccurrenceHandle1:CAS:528:DC%2BD2MXjtFyktLk%3DOccurrenceHandle10.1016/j.jhep.2004.12.035
A. Gabizon S. Amselem D. Gorem R. Cohen S. Druckmann I. Fromer R. Chisin A. Peretz Y. Barenholz (1990)ArticleTitlePreclinical and clinical experience with a doxorubicin liposome preparationJ. Liposome Res.1 491–502
A. Gabizon T. Peretz A. Sulkes S. Amselem R. Ben-Yosef N. Ben-Baruch R. Catane S. Biran Y. Barenholz (1989)ArticleTitleSystemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyEur. J. Cancer Clin. Oncol.25 1795–1803OccurrenceHandle2632261OccurrenceHandle1:STN:280:DyaK3c3hsVKltA%3D%3DOccurrenceHandle10.1016/0277-5379(89)90350-7
M. C. Woodle D. D. Lasic (1992)ArticleTitleSterically stabilized liposomesBiochim. Biophys. Acta1113 171–199OccurrenceHandle1510996OccurrenceHandle1:CAS:528:DyaK38XltlOnu78%3D
D. Papahadjopoulos T. M. Allen A. Gabizon E. Mayhew K. Matthay S. K. Huang K. Lee M. C. Woodle D. D. Lasic C. Redemann M. F. Martin (1991)ArticleTitleSterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyProc. Natl. Acad. Sci. USA88 11460–11464OccurrenceHandle1763060OccurrenceHandle1:CAS:528:DyaK38XmslWjsg%3D%3DOccurrenceHandle10.1073/pnas.88.24.11460
S. I. Jeon J. H. Lee J. D. Andrade P. G. GennesParticleDe (1991)ArticleTitleProtein–surface interactions in the presence of polyethylene oxide. I Simplified theoryJ. Colloid Interface Sci.142 149–158OccurrenceHandle1:CAS:528:DyaK3MXovVKisg%3D%3DOccurrenceHandle10.1016/0021-9797(91)90043-8
A. Gabizon R. Catane B. Uziely B. Kaufman T. Safra R. Cohen F. Martin A. Huang Y. Barenholz (1994)ArticleTitleProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res.54 987–992OccurrenceHandle8313389OccurrenceHandle1:CAS:528:DyaK2cXhslegs70%3D
L. Illum L. O. Jacobsen R. H. Muller E. Mak S. S. Davis (1987)ArticleTitleSurface characteristics and the interaction of colloidal particles with mouse peritoneal macrophagesBiomaterials8 113–117OccurrenceHandle3580470OccurrenceHandle1:CAS:528:DyaL2sXitF2ntLY%3DOccurrenceHandle10.1016/0142-9612(87)90099-8
S. M. Moghimi I. S. Muir L. Illum S. S. Davis V. Kolb-Bachofen (1993)ArticleTitleCoating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serumBiochim. Biophys. Acta1179 157–165OccurrenceHandle8218358OccurrenceHandle1:CAS:528:DyaK2cXjsl2ntw%3D%3DOccurrenceHandle10.1016/0167-4889(93)90137-E
R. Gref Y. Minamitake M. T. Peracchia V. Trubetskoy V. Torchilin R. Langer (1994)ArticleTitleBiodegradable long-circulating polymeric nanospheresScience263 1600–1603OccurrenceHandle8128245OccurrenceHandle1:CAS:528:DyaK2cXit1KktLc%3D
M. T. Peracchia S. Harnisch H. Pinto-Alphandary A. Gulik J. C. Dedieu D. Desmaële J. D’Angelo R. H. Müller P. Couvreur (1999)ArticleTitleVisualization ofin vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticleBiomaterials20 1269–1275OccurrenceHandle10403044OccurrenceHandle1:CAS:528:DyaK1MXktVyjtbk%3DOccurrenceHandle10.1016/S0142-9612(99)00021-6
G. Storm S. O. Belliot T. Daemen D. D. Lasic (1995)ArticleTitleSurface modification of nanoparticles to oppose uptake by the mononuclear phagocyte systemAdv. Drug Deliv. Rev.17 31–48OccurrenceHandle1:CAS:528:DyaK2MXps1Wltbk%3DOccurrenceHandle10.1016/0169-409X(95)00039-A
S. M. Moghimi A. C. Hunter J. C. Murray (2001)ArticleTitleLong-circulating and target-specific nanoparticles: theory to practicePharmacol. Rev.53 283–318OccurrenceHandle11356986OccurrenceHandle1:CAS:528:DC%2BD3MXkt1Gnurc%3D
H. F. Dvorak J. A. Nagy J. T. Dvorak A. M. Dvorak (1988)ArticleTitleIdentification and characterization of the blood vessels of solid tumors that are leaky to circulating macromoleculesAm. J. Pathol.133 95–109OccurrenceHandle2459969OccurrenceHandle1:STN:280:DyaL1M%2FitlCksQ%3D%3D
Y. Noguchi J. Wu R. Duncan J. Strohalm K. Ulbrich T. Akaike H. Maeda (1998)ArticleTitleEarly phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissuesJpn. J. Cancer Res.89 307–314OccurrenceHandle9600125OccurrenceHandle1:CAS:528:DyaK1cXis1arsbY%3D
H. Maeda J. Wu T. Sawa Y. Matsumura K. Hori (2000)ArticleTitleTumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ. Control. Release65 271–284OccurrenceHandle10699287OccurrenceHandle1:CAS:528:DC%2BD3cXhtl2qsLo%3DOccurrenceHandle10.1016/S0168-3659(99)00248-5
P. Calvo B. Gouritin H. Villarroya F. Eclancher C. Giannavola C. Klein J. P. Andreux P. Couvreur (2002)ArticleTitleQuantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the ratEur. J. Neurosci.15 1317–1326OccurrenceHandle11994126OccurrenceHandle10.1046/j.1460-9568.2002.01967.x
P. G. Rose (2005)ArticleTitlePegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancerOncologist10 205–214OccurrenceHandle15793224OccurrenceHandle1:CAS:528:DC%2BD2MXjsFSnsbg%3DOccurrenceHandle10.1634/theoncologist.10-3-205
A. N. Gordon C. O. Granai P. G. Rose J. Hainsworth A. Lopez C. Weissman R. Rosales T. Sharpington (2000)ArticleTitlePhase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancerJ. Clin. Oncol.18 3093–3100OccurrenceHandle10963637OccurrenceHandle1:CAS:528:DC%2BD3cXntVCgsb4%3D
A. N. Gordon J. T. Fleagle D. Guthrie D. E. Parkin M. E. Gore A. J. Lacave (2001)ArticleTitleRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicinversus topotecanJ. Clin. Oncol.19 3312–3322OccurrenceHandle11454878OccurrenceHandle1:CAS:528:DC%2BD3MXlvVamsr8%3D
O. Lyass B. Uziely R. Ben Yosef D. Tzemach N. I. Heshing M. Lotem G. Brufman A. Gabizon (2000)ArticleTitleCorrelation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaCancer89 1037–1047OccurrenceHandle10964334OccurrenceHandle1:CAS:528:DC%2BD3cXmsFSqs7o%3DOccurrenceHandle10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
J. M. Ferrero B. Weber D. Lepille H. Orfeuvre M. Combe F. Mayer B. Leduc H. Bourgeois D. Paraiso E. Pujate-Lauraine (2004)ArticleTitleCarboplatin (PA) and pegylated liposomal doxorubicin in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): survival results of a GINECO phase II trialProc. Am. Soc. Clin. Oncol.23 467s
P. Sapra T. M. Allen (2002)ArticleTitleInternalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugsCancer Res.62 7190–7194OccurrenceHandle12499256OccurrenceHandle1:CAS:528:DC%2BD3sXhtVyrtQ%3D%3D
P. Sapra T. M. Allen (2003)ArticleTitleLigand-targeted liposomal anticancer drugsProg. Lipid Res.42 439–462OccurrenceHandle12814645OccurrenceHandle1:CAS:528:DC%2BD3sXks1altLY%3DOccurrenceHandle10.1016/S0163-7827(03)00032-8
V. P. Torchilin (2005)ArticleTitleRecent advances with liposomes as pharmaceutical carriersNat. Rev. Drug Discov.4 145–160OccurrenceHandle15688077OccurrenceHandle1:CAS:528:DC%2BD2MXpt1WlsA%3D%3DOccurrenceHandle10.1038/nrd1632
T. L. Andresen S. S. Jensen K. Jorgensen (2005)ArticleTitleAdvanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug releaseProg. Lipid Res.44 68–97OccurrenceHandle15748655OccurrenceHandle1:CAS:528:DC%2BD2MXhvVCjtb8%3DOccurrenceHandle10.1016/j.plipres.2004.12.001
K. Maruyama O. Ishida T. Takizawa K. Moribe (1999)ArticleTitlePossibility of active targeting to tumor tissues with liposomesAdv. Drug Deliv. Rev.40 89–102OccurrenceHandle10837782OccurrenceHandle1:CAS:528:DyaK1MXmsFajsLc%3DOccurrenceHandle10.1016/S0169-409X(99)00042-3
J. W. Park D. B. Kirpotin K. Hong R. Shalaby Y. Shao U. B. Nielsen J. D. Marks D. Papahadjopoulos C. C. Benz (2001)ArticleTitleTumor targeting using anti-her2 immunoliposomesJ. Control. Release74 95–113OccurrenceHandle11489487OccurrenceHandle1:CAS:528:DC%2BD3MXlslansrk%3DOccurrenceHandle10.1016/S0168-3659(01)00315-7
J. A. Kamps G. A. Koning M. J. Velinova H. W. Morselt M. Wilkens A. Gorter J. Donga G. L. Scherphof (2000)ArticleTitleUptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancerJ. Drug Target.8 235–245OccurrenceHandle11144234OccurrenceHandle1:CAS:528:DC%2BD3cXoslaitbg%3DOccurrenceHandle10.3109/10611860008997902
G. A. Koning H. W. M. Morselt A. Gorter T. M. Allen S. Zalipsky G. L. Scherphof J. A. A. M. Kamps (2003)ArticleTitleInteraction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. Anin vitro comparisonPharm. Res.20 1249–1257OccurrenceHandle12948023OccurrenceHandle1:CAS:528:DC%2BD3sXmtVGrtb0%3DOccurrenceHandle10.1023/A:1025009300562
R. M. Schiffelers G. A. Koning T. L. M. HagenParticleTen M. H. A. M. Fens A. J. Schraa A. P. C. A. Janssen R. J. Kok G. Molema G. Storm (2003)ArticleTitleAnti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicinJ. Control. Release91 115–122OccurrenceHandle12932643OccurrenceHandle1:CAS:528:DC%2BD3sXmsVSkurw%3DOccurrenceHandle10.1016/S0168-3659(03)00240-2
J. N. Moreira T. Ishida R. Gaspar T. M. Allen (2002)ArticleTitleUse of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicityPharm. Res.19 265–269OccurrenceHandle11934232OccurrenceHandle1:CAS:528:DC%2BD38XisFGgu74%3DOccurrenceHandle10.1023/A:1014434732752
H. Hatakeyama H. Akita K. Maruyama T. Suhara H. Harashima (2004)ArticleTitleFactors governing thein vivo tissue uptake of transferrin-coupled polyethylene glycol liposomesin vivoInt. J. Pharm.281 25–33OccurrenceHandle15288340OccurrenceHandle1:CAS:528:DC%2BD2cXmtFCmurk%3DOccurrenceHandle10.1016/j.ijpharm.2004.05.025
D. A. Eavarone X. Yu R. V. Bellamkonda (2000)ArticleTitleTargeted drug delivery to C6 glioma by transferrin-coupled liposomesJ. Biomed. Mater. Res.51 10–14OccurrenceHandle10813739OccurrenceHandle1:CAS:528:DC%2BD3cXjsFygsbc%3DOccurrenceHandle10.1002/(SICI)1097-4636(200007)51:1<10::AID-JBM2>3.0.CO;2-R
O. Ishida K. Maruyama H. Tanahashi M. Iwatsuru K. Sasaki M. Eriguchi H. Yanagie (2001)ArticleTitleLiposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumorsin vivoPharm. Res.18 1042–1048OccurrenceHandle11496943OccurrenceHandle1:CAS:528:DC%2BD3MXlsV2itbo%3DOccurrenceHandle10.1023/A:1010960900254
R. J. Lee P. S. Low (1994)ArticleTitleDelivery of liposomes into cultured KB cells via folate receptor-mediated endocytosisJ. Biol. Chem.269 3198–3204OccurrenceHandle8106354OccurrenceHandle1:CAS:528:DyaK2cXhsVeqsbk%3D
S. Ni S. M. Stephenson R. J. Lee (2002)ArticleTitleFolate receptor targeted delivery of liposomal daunorubicin into tumor cellsAnticancer Res.22 2131–2135OccurrenceHandle12174894OccurrenceHandle1:CAS:528:DC%2BD38XmsF2ltrY%3D
X. Q. Pan H. Wang R. J. Lee (2003)ArticleTitleAntitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft modelPharm. Res.20 417–422OccurrenceHandle12669962OccurrenceHandle1:CAS:528:DC%2BD3sXhslGrtrw%3DOccurrenceHandle10.1023/A:1022656105022
J. J. Sudimack D. Adams J. Rotaru S. Shukla J. Yan M. Sekido R. F. Barth W. Tjarks R. J. Lee (2002)ArticleTitleFolate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cellsin vitro for neutron capture therapyPharm. Res.19 1502–1508OccurrenceHandle12425468OccurrenceHandle1:CAS:528:DC%2BD38XnsFSgsbY%3DOccurrenceHandle10.1023/A:1020408716807
P. Opanasopit M. Sakai M. Nishikawa S. Kawakami F. Yamashita M. Hashida (2002)ArticleTitleInhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriersJ. Control. Release80 283–294OccurrenceHandle11943405OccurrenceHandle1:CAS:528:DC%2BD38XisFyrsbg%3DOccurrenceHandle10.1016/S0168-3659(02)00006-8
B. Stella S. Arpicco M. T. Peracchia D. Desmaele J. Hoebeke M. Renoir J. D’Angelo L. Cattel P. Couvreur (2000)ArticleTitleDesign of folic acid-conjugated nanoparticles for drug targetingJ. Pharm. Sci.89 1452–1464OccurrenceHandle11015690OccurrenceHandle1:CAS:528:DC%2BD3cXnvVygtrw%3DOccurrenceHandle10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
H. Wartlick K. Michaelis S. Balthasar K. Strebhardt J. Kreuter K. Langer (2004)ArticleTitleHighly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cellsJ. Drug Target.12 461–471OccurrenceHandle15621671OccurrenceHandle1:CAS:528:DC%2BD2cXhtFSisLfEOccurrenceHandle10.1080/10611860400010697
M. B. Yatvin W. Kreutz B. A. Horwitz M. Shinitzky (1980)ArticleTitlepH-sensitive liposomes: possible clinical implicationsScience210 1253–1255OccurrenceHandle7434025OccurrenceHandle1:CAS:528:DyaL3MXhsVGhurw%3D
J. Shin P. Shum D. H. Thompson (2003)ArticleTitleAcid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipidsJ. Control. Release91 187–200OccurrenceHandle12932651OccurrenceHandle1:CAS:528:DC%2BD3sXmsVSrsrw%3DOccurrenceHandle10.1016/S0168-3659(03)00232-3
G. Helmlinger F. Yuan M. Dellian R. K. Jain (1997)ArticleTitleInterstitial pH andpO2 gradients in solid tumorsin vivo: high-resolution measurements reveal a lack of correlationNat. Med.3 177–182OccurrenceHandle9018236OccurrenceHandle1:CAS:528:DyaK2sXpsVOktw%3D%3DOccurrenceHandle10.1038/nm0297-177
G. Helmlinger A. Sckell M. Dellian N. S. Forbes R. K. Jain (2002)ArticleTitleAcid production in glycolysis-impaired tumors provides new insights into tumor metabolismClin. Cancer Res.8 1284–1291OccurrenceHandle11948144OccurrenceHandle1:CAS:528:DC%2BD38XjsF2ltb4%3D
E. Fattal P. Couvreur C. Dubernet (2004)ArticleTitle“Smart” delivery of antisense oligonucleotides by anionic pH-sensitive liposomesAdv. Drug Deliv. Rev.56 931–946OccurrenceHandle15066753OccurrenceHandle1:CAS:528:DC%2BD2cXivVGitLs%3DOccurrenceHandle10.1016/j.addr.2003.10.037
S. Simoes J. N. Moreira C. Fonseca N. Düzgünes M. C. Pedroso de Lima (2004)ArticleTitleOn the formulation of pH-sensitive liposomes with long circulation timesAdv. Drug Deliv. Rev.56 947–965OccurrenceHandle15066754OccurrenceHandle1:CAS:528:DC%2BD2cXivVGitLg%3DOccurrenceHandle10.1016/j.addr.2003.10.038
A. Mori A. L. Klibanov V. P. Torchilin L. Huang (1991)ArticleTitleInfluence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomesin vivoFEBS Lett.284 263–266OccurrenceHandle2060647OccurrenceHandle1:CAS:528:DyaK3MXkslyrsr4%3DOccurrenceHandle10.1016/0014-5793(91)80699-4
K. Kono K. Zenitani T. Takagishi (1994)ArticleTitleNovel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol) derivative with carboxyl groupsBiochim. Biophys. Acta1193 1–9OccurrenceHandle8038177OccurrenceHandle1:CAS:528:DyaK2cXls1ertrY%3DOccurrenceHandle10.1016/0005-2736(94)90325-5
E. Roux M. Francis F. M. Winnik J. C. Leroux (2002)ArticleTitlePolymer based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugsInt. J. Pharm.242 25–36OccurrenceHandle12176222OccurrenceHandle1:CAS:528:DC%2BD38Xmt1ygur8%3DOccurrenceHandle10.1016/S0378-5173(02)00183-7
D. Collins D. C. Litzinger L. Huang (1990)ArticleTitleStructural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three different diacylsuccinylglycerolsBiochim. Biophys. Acta1025 234–242OccurrenceHandle2364079OccurrenceHandle1:CAS:528:DyaK3cXlvFOktLY%3DOccurrenceHandle10.1016/0005-2736(90)90102-T
K. Kono T. Igawa T. Takagishi (1997)ArticleTitleCytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivativeBiochim. Biophys. Acta1325 143–154OccurrenceHandle9168140OccurrenceHandle1:CAS:528:DyaK2sXjt1WrsrY%3DOccurrenceHandle10.1016/S0005-2736(96)00244-1
V. A. Slepushkin S. Simoens P. Dazin M. S. Newman L. S. Guo M. C. Pedroso de Lima N. Duzgunes (1997)ArticleTitleSterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulationin vivoJ. Biol. Chem.272 2382–2388OccurrenceHandle8999949OccurrenceHandle1:CAS:528:DyaK2sXotFarsg%3D%3DOccurrenceHandle10.1074/jbc.272.4.2382
D. Liu L. Huang (1990)ArticleTitlepH-Sensitive, plasma-stable liposomes with relatively prolonged residence in circulationBiochim. Biophys. Acta1022 348–354OccurrenceHandle2317486OccurrenceHandle1:CAS:528:DyaK3cXhvVGks7Y%3DOccurrenceHandle10.1016/0005-2736(90)90284-U
M. B. Yatvin J. N. Weinstein W. H. Dennis R. Blumenthal (1978)ArticleTitleDesign of liposomes for enhanced local release of drugs by hyperthermiaScience202 1290–1293OccurrenceHandle364652OccurrenceHandle1:CAS:528:DyaE1MXpt1elsQ%3D%3D
G. Kong G. Anyarambhatla W. P. Petros R. D. Braun O. M. Colvin D. Needham M. W. Dewhirst (2000)ArticleTitleEfficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug releaseCancer Res.60 6950–6957OccurrenceHandle11156395OccurrenceHandle1:CAS:528:DC%2BD3MXjsVOjtA%3D%3D
D. Needham G. Anyarambhatla G. Kong M. W. Dewhirs (2000)ArticleTitleA new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft modelCancer Res.60 1197–1201OccurrenceHandle10728674OccurrenceHandle1:CAS:528:DC%2BD3cXhvFWrsb0%3D
T. L. Andresen J. Davidsen M. Begtrup O. G. Mouritsen K. Jorgensen (2004)ArticleTitleEnzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugsJ. Med. Chem.47 1694–1703OccurrenceHandle15027860OccurrenceHandle1:CAS:528:DC%2BD2cXhsVOit70%3DOccurrenceHandle10.1021/jm031029r
T. L. Andresen O. G. Mouritsen M. Begtrup K. Jorgensen (2002)ArticleTitlePhospholipase A2 activity: dependence on liposome surface charge and polymer coverageBiophys. J.82 148c
C. C. Pak R. K. Erukulla P. L. Ahl A. S. Janoff P. Meers (1999)ArticleTitleElastase activated liposomal delivery to nucleated cellsBiochim. Biophys. Acta1419 111–126OccurrenceHandle10407064OccurrenceHandle1:CAS:528:DyaK1MXltV2mtLk%3DOccurrenceHandle10.1016/S0005-2736(98)00256-9
S. C. Davis F. C. SzokaSuffixJr. (1998)ArticleTitleCholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposomeBioconjug. Chem.9 783–792OccurrenceHandle9815173OccurrenceHandle1:CAS:528:DyaK1cXmsVWjs7w%3DOccurrenceHandle10.1021/bc980047y
A. Mueller B. Bondurant D. F. O’Brien (2000)ArticleTitleVisible-light stimulated destabilization of PEG-liposomesMacromolecules33 4799–4804OccurrenceHandle1:CAS:528:DC%2BD3cXjs1KksL4%3DOccurrenceHandle10.1021/ma000055l
B. Bonnemain (1998)ArticleTitleSuperparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A reviewJ. Drug Target.6 167–174OccurrenceHandle9888302OccurrenceHandle1:CAS:528:DyaK1MXkvFKguw%3D%3DOccurrenceHandle10.3109/10611869808997890
D. Pouliquen J. J. JeuneParticleLe R. Perdrisot A. Ermias P. Jallet (1991)ArticleTitleIron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolismMagn. Reson. Imaging9 275–283OccurrenceHandle1881245OccurrenceHandle1:CAS:528:DyaK3MXlslyhtbw%3DOccurrenceHandle10.1016/0730-725X(91)90412-F
E. Okon D. Pouliquen P. Okon Z. V. Kovaleva T. P. Stepanova S. G. Lavit B. N. Kudryavtsev P. Jallet (1994)ArticleTitleBiodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical studyLab. Invest.71 895–903OccurrenceHandle7807971OccurrenceHandle1:CAS:528:DyaK2MXjs12gsbg%3D
A. Chachuat B. Bonnemain (1995)ArticleTitleEuropean clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patientsRadiology35 S274–S276OccurrenceHandle1:STN:280:DyaK287gvVansw%3D%3D
S. Kubaska D. V. Sahani S. Saini P. F. Hahn E. Halpern (2001)ArticleTitleDual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterisationClin. Radiol.56 410–415OccurrenceHandle11384141OccurrenceHandle1:STN:280:DC%2BD3MzhtFKlsA%3D%3DOccurrenceHandle10.1053/crad.2000.0673
R. Weissleder G. Elizondo D. D. Stark P. F. Hahn J. Marfil J. F. Gonzalez S. Saini L. E. Todd J. T. Ferrucci (1989)ArticleTitleThe diagnosis of splenic lymphoma by MR imaging: value of superparamagnetic iron oxideA.J.R. Am. J. Roentgenol.152 175–180OccurrenceHandle1:STN:280:DyaL1M%2FnsVCqsg%3D%3D
A. Iannone R. L. Magin T. Walczak M. Federico H. M. Swartz A. Tomasi V. Vannini (1991)ArticleTitleBlood clearance of dextran magnetite particles determined by a noninvasivein vivo ESR methodMagn. Reson. Med.22 435–442OccurrenceHandle1725919OccurrenceHandle1:STN:280:DyaK383lt1Kqsg%3D%3D
R. Weissleder A. Bogdanov E. A. Neuwelt M. Papisov (1995)ArticleTitleLong-circulating iron oxides for MR imagingAdv. Drug Deliv. Rev.16 321–334OccurrenceHandle1:CAS:528:DyaK2MXpt1amt7s%3DOccurrenceHandle10.1016/0169-409X(95)00033-4
K. Turetschek S. Huber E. Floyd T. Helbich T. P. Roberts D. M. Shames K. S. Tarlo M. F. Wendland R. C. Brasch (2001)ArticleTitleMR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlationRadiology218 562–569OccurrenceHandle11161179OccurrenceHandle1:STN:280:DC%2BD3M3lvVehsw%3D%3D
Y. Anzai S. McLachlan M. Morris R. Saxton R. B. Lufkin (1994)ArticleTitleDextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neckAm. J. Neuroradiol.15 87–94OccurrenceHandle7511324OccurrenceHandle1:STN:280:DyaK2c7ovFCkug%3D%3D
K. Lind M. Kresse N. P. Debus R. H. Muller (2002)ArticleTitleA novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphograpy: comparison of physicochemical properties and thein vivo behaviourJ. Drug Target.10 221–230OccurrenceHandle12075823OccurrenceHandle1:CAS:528:DC%2BD38XjslSlt7s%3DOccurrenceHandle10.1080/10611860290022651
A. Moore R. Weissleder A. BogdanovSuffixJr. (1997)ArticleTitleUptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophagesJ. Magn. Reson. Imaging7 1140–1145OccurrenceHandle9400860OccurrenceHandle1:STN:280:DyaK1c%2Fmt1SgsA%3D%3D
A. Moore J. P. Basilion E. A. Chiocca R. Weissleder (1998)ArticleTitleMeasuring transferrin receptor gene expression by NMR imagingBiochim. Biophys. Acta1402 239–249OccurrenceHandle9606982OccurrenceHandle1:CAS:528:DyaK1cXivVOqtLY%3DOccurrenceHandle10.1016/S0167-4889(98)00002-0
P. Varallyay G. Nesbit L. L. Muldoon R. R. Nixon J. Delashaw J. I. Cohen A. Petrillo D. Rink E. A. Neuwelt (2002)ArticleTitleComparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumorsAm. J. Neuroradiol.23 510–519OccurrenceHandle11950637
L. G. Remsen C. I. McCormick S. Roman-Goldstein G. Nilaver R. Weissleder A. Bogdanov I. Hellstrom R. A. Kroll E. A. Neuwelt (1996)ArticleTitleMR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosisAm. J. Neuroradiol.17 411–418OccurrenceHandle8881233OccurrenceHandle1:STN:280:DyaK2s%2FjsFGrtw%3D%3D
D. Artemov N. Mori B. Okollie Z. M. Bhujwalla (2003)ArticleTitleMR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticlesMagn. Reson. Med.49 403–408OccurrenceHandle12594741OccurrenceHandle1:CAS:528:DC%2BD3sXisVGktL4%3DOccurrenceHandle10.1002/mrm.10406
M. Shinkai M. Yanase M. Suzuki H. Honda T. Wakabayashi J. Yoshida T. Kobayashi (1999)ArticleTitleIntracellular hyperthermia for cancer using magnetite cationic liposomesJ. Magn. Magn. Mater.194 176–184OccurrenceHandle1:CAS:528:DyaK1MXitVKltrs%3DOccurrenceHandle10.1016/S0304-8853(98)00586-1
M. Yanase M. Shinkai H. Honda T. Wakabayashi J. Yoshida T. Kobayashi (1998)ArticleTitleAntitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomesJpn. J. Cancer Res.89 775–782OccurrenceHandle9738985OccurrenceHandle1:CAS:528:DyaK1cXltlCju78%3D
I. Hilger W. Andrä R. Hergt R. Hiergeist H. Schubert W. A. Kaiser (2001)ArticleTitleElectromagnetic heating of breast tumors in interventional radiology:in vitro andin vivo studies in human cadavers and miceRadiology218 570–575OccurrenceHandle11161180OccurrenceHandle1:STN:280:DC%2BD3M3lvVehsA%3D%3D
A. Jordan P. Wust R. Scholz H. Faehling J. Krause R. Felix (1997) Magnetic fluid hyperthermia (MFH) U. Hafeli W. Schutt J. Teller U. Hdfeli W. Schutt M. Zborowski (Eds) Scientific and Clinical Applications of Magnetic Carriers Plenum Press New York 569–595
A. Jordan R. Scholz K. Maier-Hauff M. Johannsen P. Wust J. Nadobny H. Schirra H. Schmidt S. Deger S. Loening W. Lanksch R. Felix (2001)ArticleTitlePresentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermiaJ. Magn. Magn. Mater.225 118–126OccurrenceHandle1:CAS:528:DC%2BD3MXislaiurc%3DOccurrenceHandle10.1016/S0304-8853(00)01239-7
A. Halbreich J. Roger J. N. Pons D. Geldwerth M. F. SilvaParticleDa M. Roudier J. C. Bacri (1998)ArticleTitleBiomedical applications of maghemite ferrofluidBiochimie80 379–390OccurrenceHandle9782379OccurrenceHandle1:CAS:528:DyaK1cXmt1Sntbw%3DOccurrenceHandle10.1016/S0300-9084(00)80006-1
J. C. Bacri M. F. SilvaParticleDa R. Perzynski J. N. Pons J. Roger D. Sabolovic A. Halbreich (1997) Use of magnetic nanoparticles for thermolysis of cells in a ferrofluid U. Hafeli W. Schutt J. Teller U. Hdfeli W. Schutt M. Zborowski (Eds) Scientific and Clinical Applications of Magnetic Carriers Plenum Press New York 597–606
A. Jordan R. Scholz P. Wust H. Schirra (1999)ArticleTitleEndocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cellsin vitroJ. Magn. Magn. Mater.194 185–196OccurrenceHandle1:CAS:528:DyaK1MXitVKltrg%3DOccurrenceHandle10.1016/S0304-8853(98)00558-7
M. Shinkai B. Le H. Honda K. Yoshikawa K. Shimizu S. Saga T. Wakabayashi J. Yoshida T. Kobayashi (2001)ArticleTitleTargeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomesJpn. J. Cancer Res.92 1138–1145OccurrenceHandle11676866OccurrenceHandle1:CAS:528:DC%2BD3MXptVGgu7g%3D
F. Sonvico S. Mornet S. Vasseur C. Dubernet D. Jaillard J. Degrouard J. Hoebeke E. Duguet P. Colombo P. Couvreur (2005)ArticleTitleFolate-conjugated iron oxide nanoparticles for solid tumor targeting as potential “Specific Magnetic Hyperthermia Mediators: Synthesis, Physicochemical Characterization, andin Vitro Experiments”Bioconjug. Chem.16 1181–1188OccurrenceHandle16173796OccurrenceHandle1:CAS:528:DC%2BD2MXpsleqsrs%3DOccurrenceHandle10.1021/bc050050z
C. M. Pitsillides E. K. Joe X. Wie R. R. Anderson C. P. Lin (2003)ArticleTitleSelective cell targeting with light-adsorbing microparticles and nanoparticlesBiophys. J.84 4023–4032OccurrenceHandle12770906OccurrenceHandle1:CAS:528:DC%2BD3sXksVKnsbg%3DOccurrenceHandle10.1016/S0006-3495(03)75128-5
C. P. Lin M. W. Kelly S. A. Sibayan M. A. Latina R. R. Anderson (1999)ArticleTitleSelective cell killing by microparticle absorption of pulsed laser radiationIEEE J. Sel. Top. Quantum Electron.5 963–968OccurrenceHandle1:CAS:528:DyaK1MXntVWrurw%3DOccurrenceHandle10.1109/2944.796318
F. Shi A. L. Rakhmilevich C. P. Heise K. Oshikawa P. M. Sondel N. S. Yang D. M. Mahvi (2002)ArticleTitleIntratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine modelMol. Cancer Ther.1 949–957OccurrenceHandle12481417OccurrenceHandle1:CAS:528:DC%2BD3sXmvFOntA%3D%3D
K. Kawabata T. Takakura M. Hashida (1995)ArticleTitleThe fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptakePharm. Res.12 825–830OccurrenceHandle7667185OccurrenceHandle1:CAS:528:DyaK2MXmtV2qurc%3DOccurrenceHandle10.1023/A:1016248701505
K. Ewert A. Ahmad H. M. Evans H. W. Schmidt C. R. Safinya (2002)ArticleTitleEfficient synthesis and cell-transfection properties of a new multivalent cationic lipid for nonviral gene deliveryJ. Med. Chem.45 5023–5029OccurrenceHandle12408712OccurrenceHandle1:CAS:528:DC%2BD38XnvV2lurw%3DOccurrenceHandle10.1021/jm020233w
H. Gao K. M. Hui (2001)ArticleTitleSynthesis of a novel series of cationic lipids that can act as efficient gene delivery vehicles through systematic heterocyclic substitution of cholesterol derivativesGene Ther.8 855–863OccurrenceHandle11423933OccurrenceHandle1:CAS:528:DC%2BD3MXktFOrtr0%3DOccurrenceHandle10.1038/sj.gt.3301471
X. Gao L. Huang (1996)ArticleTitlePotentiation of cationic liposome-mediated gene delivery by polycationsBiochemistry35 1027–1036OccurrenceHandle8547238OccurrenceHandle1:CAS:528:DyaK28XhsFKjsA%3D%3DOccurrenceHandle10.1021/bi952436a
N. T. Ueno C. Bartholomeusz W. Xia P. Anklesaria E. M. Bruckheimer E. Mebel R. Paul S. Li G. H. Yo L. Huang M. C. Hung (2002)ArticleTitleSystemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A geneCancer Res.62 6712–6716OccurrenceHandle12438271OccurrenceHandle1:CAS:528:DC%2BD38XovFOksLc%3D
A. Y. Nikitin M. I. Juarez-Perez S. Li L. Huang W. H. Lee (1999)ArticleTitleRB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/− miceProc. Natl. Acad. Sci. USA96 3916–3921OccurrenceHandle10097138OccurrenceHandle1:CAS:528:DyaK1MXjslChsLk%3DOccurrenceHandle10.1073/pnas.96.7.3916
T. B. Wyman F. Nicol O. Zelphati P. V. Scaria C. Plank F. C. SzokaSuffixJr. (1997)ArticleTitleDesign, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayersBiochemistry36 3008–3017OccurrenceHandle9062132OccurrenceHandle1:CAS:528:DyaK2sXhslGjsr4%3DOccurrenceHandle10.1021/bi9618474
G. Y. Wu C. H. Wu (1987)ArticleTitleReceptor-mediatedin vitro gene transformation by a soluble DNA carrier systemJ. Biol. Chem.262 4429–4432OccurrenceHandle3558345OccurrenceHandle1:CAS:528:DyaL2sXhslShsL0%3D
C. M. Ward M. L. Read L. W. Seymour (2001)ArticleTitleSystemic circulation of poly(l-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapyBlood97 2221–2229OccurrenceHandle11290582OccurrenceHandle1:CAS:528:DC%2BD3MXivFOgt78%3DOccurrenceHandle10.1182/blood.V97.8.2221
O. Boussif F. Lezoualc’h M. A. Zanta M. D. Mergny D. Scherman B. Demeneix J. P. Behr (1995)ArticleTitleA versatile vector for gene and oligonucleotide transfer into cells in culture andin vivo: polyethylenimineProc. Natl. Acad. Sci. USA92 7297–7301OccurrenceHandle7638184OccurrenceHandle1:CAS:528:DyaK2MXntlKmt7s%3DOccurrenceHandle10.1073/pnas.92.16.7297
A. Kichler C. Leborgne E. Coeytaux O. Danos (2001)ArticleTitlePolyethylenimine-mediated gene delivery: a mechanistic studyJ. Gene Med.3 135–144OccurrenceHandle11318112OccurrenceHandle1:STN:280:DC%2BD3MvkslGksQ%3D%3DOccurrenceHandle10.1002/jgm.173
H. Lee J. H. Jeong T. G. Park (2002)ArticleTitlePEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicityJ. Control. Release79 283–291OccurrenceHandle11853938OccurrenceHandle1:CAS:528:DC%2BD38XhtlSlsbo%3DOccurrenceHandle10.1016/S0168-3659(02)00002-0
E. Wagner M. Zenke M. Cotten H. Beug M. L. Birnstiel (1990)ArticleTitleTransferrin-polycation conjugates as carriers for DNA uptake into cellsProc. Natl. Acad. Sci. USA87 3410–3414OccurrenceHandle2333290OccurrenceHandle1:CAS:528:DyaK3MXitVWjtrc%3DOccurrenceHandle10.1073/pnas.87.9.3410
W. Suh J. K. Chung S. H. Park S. W. Kim (2001)ArticleTitleAnti-JL1 antibody-conjugated poly(l-lysine) for targeted gene delivery to leukemia T cellsJ. Control. Release72 171–178OccurrenceHandle11389996OccurrenceHandle1:CAS:528:DC%2BD3MXktVGks70%3DOccurrenceHandle10.1016/S0168-3659(01)00273-5
C. M. Ward M. Pechar D. Oupicky K. Ulbrich L. W. Seymour (2002)ArticleTitleModification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targetingin vitro and prolonged plasma circulationin vivoJ. Gene Med.4 536–547OccurrenceHandle12221647OccurrenceHandle1:CAS:528:DC%2BD38XosVWru74%3DOccurrenceHandle10.1002/jgm.296
R. Kircheis S. Schuller S. Brunner M. Ogris K. H. Heider W. Zauner E. Wagner (1999)ArticleTitlePolycation-based DNA complexes for tumor-targeted gene deliveryin vivoJ. Gene Med.1 111–120OccurrenceHandle10738575OccurrenceHandle1:CAS:528:DyaK1MXjvVCmtLk%3DOccurrenceHandle10.1002/(SICI)1521-2254(199903/04)1:2<111::AID-JGM22>3.0.CO;2-Y
G. Stingl E. B. Brocker R. Mertelsmann K. Wolff S. Schreiber E. Kampgen A. Schneeberger W. Dummer U. Brennscheid H. Veelken M. L. Birnstiel K. Zatloukal W. Schmidt G. Maass E. Wagner M. Baschle M. Giese E. R. Kempe H. A. Weber T. Voigt (1996)ArticleTitlePhase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 geneHum. Gene Ther.7 551–563OccurrenceHandle8800750OccurrenceHandle1:CAS:528:DyaK28Xit12ht74%3D
J. Chen S. Gamou A. Takayanagi N. Shimizu (1994)ArticleTitleA novel gene delivery system using EGF receptor-mediated endocytosisFEBS Lett.338 167–169OccurrenceHandle8307175OccurrenceHandle1:CAS:528:DyaK2cXhsFGitbY%3DOccurrenceHandle10.1016/0014-5793(94)80357-9
A. Boletta A. Benigni J. Lutz G. Remuzzi M. R. Soria L. Monaco (1997)ArticleTitleNonviral gene delivery to the rat kidney with polyethylenimineHum. Gene Ther.8 1243–1251OccurrenceHandle9215741OccurrenceHandle1:CAS:528:DyaK2sXksF2nt70%3D
M. Köping-Höggard Y. S. Mel’nikova K. M. Varum B. Lindman P. Artursson (2003)ArticleTitleRelationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery systemin vitro andin vivoJ. Gene Med.5 130–141OccurrenceHandle12539151OccurrenceHandle10.1002/jgm.327OccurrenceHandle1:CAS:528:DC%2BD3sXit1Glsr8%3D
L. Vincent J. Varet J. Y. Pille H. Bompais P. Opolon A. Maksimenko C. Malvy M. Mirshahi H. Lu J. P. Vannier C. Soria H. Li (2003)ArticleTitleEfficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis:in vitro andin vivo studiesInt. J. Cancer.105 419–429OccurrenceHandle12704680OccurrenceHandle1:CAS:528:DC%2BD3sXktlWit74%3DOccurrenceHandle10.1002/ijc.11105
P. WeteringParticleVan de J. Y. Cherng H. Talsma W. E. Hennink (1997)ArticleTitleRelation between transfection efficiency and cytotoxicity of poly(2-(dimethylamino)ethyl methacrylate)/plasmid complexesJ. Control. Release49 59–69OccurrenceHandle10.1016/S0168-3659(97)00059-X
A. El-Aneed (2004)ArticleTitleAn overview of current delivery systems in cancer gene therapyJ. Control. Release94 1–14OccurrenceHandle14684267OccurrenceHandle1:CAS:528:DC%2BD3sXpslCmu70%3DOccurrenceHandle10.1016/j.jconrel.2003.09.013
C. Chavany T. Saison-Behmoaras T. DoanParticleLe F. Puisieux P. Couvreur C. Hélène (1994)ArticleTitleAdsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increase their cellular uptakePharm. Res.11 1370–1378OccurrenceHandle7816773OccurrenceHandle1:CAS:528:DyaK2cXmtFarsrs%3DOccurrenceHandle10.1023/A:1018923301967
G. Schwab C. Chavany I. Duroux G. Goubin J. Lebeau C. Hélène T. Saison-Behmoaras (1994)ArticleTitleAntisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude miceProc. Natl. Acad. Sci. USA91 10460–10464OccurrenceHandle7937975OccurrenceHandle1:CAS:528:DyaK2MXhslelsr0%3DOccurrenceHandle10.1073/pnas.91.22.10460
L. Tondelli A. Ricca M. Laus M. Lelli G. Citro (1998)ArticleTitleHighly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheresNucleic Acids Res.26 5425–5431OccurrenceHandle9826768OccurrenceHandle1:CAS:528:DyaK1MXis1Knsw%3D%3DOccurrenceHandle10.1093/nar/26.23.5425
A. R. Thierry A. Rahman A. Dritschilo (1993)ArticleTitleOvercoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotidesBiochem. Biophys. Res. Commun.190 952–960OccurrenceHandle8094959OccurrenceHandle1:CAS:528:DyaK3sXktFGhsb0%3DOccurrenceHandle10.1006/bbrc.1993.1142
S. Vinogradov E. Batrakova A. Kabanov (1999)ArticleTitlePoly(ethylene glycol)–polyethyleneimine NanoGel TM particles: novel drug delivery systems for antisense oligonucleotidesColloids Surf., B Biointerfaces16 291–304OccurrenceHandle1:CAS:528:DyaK1MXnvFylu7Y%3DOccurrenceHandle10.1016/S0927-7765(99)00080-6
W. A. May M. L. Gishizky S. L. Lessnick L. B. Lunsford B. C. Lewis O. Delattre J. Zucman G. Thomas C. T. Dennt (1993)ArticleTitleEwing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformationProc. Natl. Acad. Sci. USA90 5752–5756OccurrenceHandle8516324OccurrenceHandle1:CAS:528:DyaK3sXltFCmsbw%3DOccurrenceHandle10.1073/pnas.90.12.5752
K. Tanaka T. Iwakuma K. Harimaya H. Sato Y. Iwamoto (1997)ArticleTitleEWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cellsJ. Clin. Invest.99 239–247OccurrenceHandle9005992OccurrenceHandle1:CAS:528:DyaK2sXntVOjug%3D%3DOccurrenceHandle10.1172/JCI119152
G. Lambert J. R. Bertrand E. Fattal F. Subra H. Pinto-Alphandary C. Malvy C. Auclair P. Couvreur (2000)ArticleTitleEWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in miceBiochem. Biophys. Res. Commun.279 401–406OccurrenceHandle11118299OccurrenceHandle1:CAS:528:DC%2BD3cXovVCntL8%3DOccurrenceHandle10.1006/bbrc.2000.3963
A. Maksimenko C. Malvy G. Lambert J. R. Bertrand E. Fattal J. Maccario P. Couvreur (2003)ArticleTitleOligonucleotides targeted against a junction oncogene are made efficient by nanotechnologiesPharm. Res.20 1565–1567OccurrenceHandle14620508OccurrenceHandle1:CAS:528:DC%2BD3sXotFClsr0%3DOccurrenceHandle10.1023/A:1026122914852
N. Toub C. Angiari D. Eboué E. Fattal J. P. Tenu T. DoanParticleLe P. Couvreur (2005)ArticleTitleCellular fate of oligonucleotides when delivered by nanocapsules of poly(isobutylcyanoacrylate)J. Control. Release106 209–213OccurrenceHandle15951045OccurrenceHandle1:CAS:528:DC%2BD2MXntlShsr8%3DOccurrenceHandle10.1016/j.jconrel.2005.03.029
Z. Hassani G. F. Lemkine P. Erbacher K. Palmier G. Alfama C. Giovannangeli J. P. Behr B. A. Demeneix (2005)ArticleTitleLipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levelsJ. Gene Med.7 198–207OccurrenceHandle15515135OccurrenceHandle1:CAS:528:DC%2BD2MXis1Kisrg%3DOccurrenceHandle10.1002/jgm.659
Y. Zhang Y. F. Zhang J. Bryant A. Charles R. J. Boado W. M. Pardridge (2004)ArticleTitleIntravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancerClin. Cancer Res.10 3667–3677OccurrenceHandle15173073OccurrenceHandle1:CAS:528:DC%2BD2cXksVKnsbg%3DOccurrenceHandle10.1158/1078-0432.CCR-03-0740
World Health Organisation. Number of Confirmed Cases of Poliomyelitis 2002–2005 (as of 12 September 2005),http://www.emro.who.int/polio/ (accessed 16 September 2005), part ofhttp://www.who.int (accessed 16 September 2005).
World Health Organisation. Smallpox,http://www.who.int/topics/smallpox/en/ (accessed 16 September 2005), part ofhttp://www.who.int (accessed 16 September 2005).
S. Maesaki (2002)ArticleTitleDrug delivery system of anti-fungal and parasitic agentsCurr. Pharm. Des.8 433–440OccurrenceHandle12069380OccurrenceHandle1:CAS:528:DC%2BD38Xis1Omtrk%3DOccurrenceHandle10.2174/1381612023395916
B. Dupont (2002)ArticleTitleOverview of the lipid formulations of amphothericin BJ. Antimicrob. Chemother.49 31–36OccurrenceHandle11801578OccurrenceHandle1:CAS:528:DC%2BD38XhsFChtbw%3DOccurrenceHandle10.1093/jac/49.1.31
O. Ringden (2002)ArticleTitleTen years' experience with liposomal amphotericin B in transplant recipients at Huddinge University HospitalJ. Antimicrob. Chemother.49 51–55OccurrenceHandle11801582OccurrenceHandle1:CAS:528:DC%2BD38XhsFChtbg%3D
S. L. Croft G. H. Coombs (2003)ArticleTitleLeishmaniasis-current chemotherapy and recent advances in the search for novel drugsTrends Parasitol.19 502–508OccurrenceHandle14580961OccurrenceHandle1:CAS:528:DC%2BD3sXosVyisL0%3DOccurrenceHandle10.1016/j.pt.2003.09.008
A. W. K. Ng K. M. Wasan (2003)ArticleTitleDevelopment of liposomal polyene antibiotics: an historical perspectiveJ. Pharm. Pharm. Sci.6 67–83OccurrenceHandle12753730OccurrenceHandle1:CAS:528:DC%2BD3sXjvVGhsbk%3D
W. J. Gibbs R. H. Drew J. R. Perfect (2005)ArticleTitleLiposomal amphotericin B: clinical experience and perspectivesExpert Rev. Anti-infect. Ther.3 167–181OccurrenceHandle15918775OccurrenceHandle1:CAS:528:DC%2BD2MXjt1ymurg%3DOccurrenceHandle10.1586/14787210.3.2.167
M. Owais G. C. Varshney A. Choudhury S. Chandra C. M. Gupta (1995)ArticleTitleChloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistantPlasmodium berghei infections in miceAntimicrob. Agents. Chemother.39 180–184OccurrenceHandle7695303OccurrenceHandle1:CAS:528:DyaK2MXislKksbw%3D
J. P. Adler-Moore R. T. Proffitt (1993)ArticleTitleDevelopment, characterization, efficacy and mode of action of Ambisome®, a unilamellar liposome formulation of amphotericin BJ. Liposome Res.3 429–450OccurrenceHandle1:CAS:528:DyaK2cXit1Klsrk%3D
H. W. Murray (2004)ArticleTitleProgress in the treatment of a neglected infectious disease: visceral leishmaniasisExpert Rev. Anti-infect. Ther.2 279–292OccurrenceHandle15482193OccurrenceHandle1:CAS:528:DC%2BD2cXislyqsr4%3DOccurrenceHandle10.1586/14787210.2.2.279
H. W. Murray (2004)ArticleTitleTreatment of visceral leishmaniasis in 2004Am. J. Trop. Med. Hyg.71 787–794OccurrenceHandle15642973
M. Larabi V. Yardley P. M. Loiseau M. Appel P. Legrand A. Gulik C. Boris S. Croft G. Barratt (2003)ArticleTitleToxicity and antileishmanial activity of a new stable lipid suspension of amphothericin BAntimicrob. Agents Chemother.47 3774–3779OccurrenceHandle14638481OccurrenceHandle1:CAS:528:DC%2BD3sXpsV2ntbw%3DOccurrenceHandle10.1128/AAC.47.12.3774-3779.2003
M. K. Basu S. Lala (2004)ArticleTitleMacrophage specific drug delivery in experimental leishmaniasisCurr. Mol. Med.4 681–689OccurrenceHandle15357216OccurrenceHandle1:CAS:528:DC%2BD2cXmvVKmt70%3DOccurrenceHandle10.2174/1566524043360186
P. Legrand G. Barratt V. Mosqueira H. Fessi J. P. Devissaguet (1999)ArticleTitlePolymeric nanocapsules as drug delivery systems: a reviewSci. Tech. Pharm.9 411–418OccurrenceHandle1:CAS:528:DC%2BD3cXjsF2jsg%3D%3D
R. Gaspar V. Preat F. R. Opperdoes M. Rolland (1992)ArticleTitleMacrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellularLeishmania donovani associated with hydrogen peroxide productionPharm. Res.9 782–787OccurrenceHandle1409361OccurrenceHandle1:CAS:528:DyaK38Xktlemuro%3DOccurrenceHandle10.1023/A:1015807706530
M. Fouarge M. Dewulf P. Couvreur M. Rolland H. Vranckx (1989)ArticleTitleDevelopment of dehydroemetine nanoparticles for the treatment of visceral leishmaniasisJ. Microencapsul.6 29–34OccurrenceHandle2565955OccurrenceHandle1:CAS:528:DyaL1MXhs1Sgsb4%3D
M. S. Espuelas P. Legrand M. A. Campanero M. Appel M. Chéron C. Gamazo G. Barratt J. M. Irache (2003)ArticleTitlePolymeric carriers for amphotericin B:in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic miceJ. Antimicrob. Chemother.52 419–427OccurrenceHandle12888593OccurrenceHandle1:CAS:528:DC%2BD3sXnt1Kjt7Y%3DOccurrenceHandle10.1093/jac/dkg351
R. Tyagi S. Lala A. K. Verma A. K. Nandy S. B. Mahato A. Maitra M. K. Basu (2005)ArticleTitleTargeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasisJ. Drug Target.13 161–171OccurrenceHandle16036304OccurrenceHandle1:CAS:528:DC%2BD2MXjvFajsb0%3D
V. C. F. Mosqueira P. M. Loiseau C. Bories P. Legrand J. P. Devissaguet G. Barratt (2004)ArticleTitleEfficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine inPlasmodium berghei-infected miceAntimicrob. Agents Chemother.48 1222–1228OccurrenceHandle15047523OccurrenceHandle1:CAS:528:DC%2BD2cXjtVKqsr4%3DOccurrenceHandle10.1128/AAC.48.4.1222-1228.2004
I. A. Bakker-Woudenberg (2002)ArticleTitleLong-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious fociInt. J. Antimicrob. Agents19 299–311OccurrenceHandle11978501OccurrenceHandle1:CAS:528:DC%2BD38XjtVeisL0%3DOccurrenceHandle10.1016/S0924-8579(02)00021-3
H. Pinto-Alphandary A. Andremont P. Couvreur (2000)ArticleTitleTargeted delivery of antibiotics using liposomes and nanoparticles: research and applicationsInt. J. Antimicrob. Agents13 155–168OccurrenceHandle10724019OccurrenceHandle1:CAS:528:DyaK1MXns1Whur0%3DOccurrenceHandle10.1016/S0924-8579(99)00121-1
R. Schiffelers G. Storm I. Bakker-Woudenberg (2001)ArticleTitleLiposome-encapsulated aminoglycosides in pre-clinical and clinical studiesJ. Antimicrob. Chemother.48 333–344OccurrenceHandle11532996OccurrenceHandle1:CAS:528:DC%2BD3MXntlSgtL8%3DOccurrenceHandle10.1093/jac/48.3.333
G. Barratt (2004)ArticleTitleColloidal drug carriers: achievements and perspectivesCell. Mol. Life Sci.60 21–37OccurrenceHandle10.1007/s000180300002
R. M. Fielding R. O. Lewis L. Moon-McDermott (1998)ArticleTitleAltered tissue distribution and elimination of Amikacin encapsulated in unilamellar, low clearance liposomes (Mikasome®)Pharm. Res.15 1775–1781OccurrenceHandle9834002OccurrenceHandle1:CAS:528:DyaK1cXnsFSns7Y%3DOccurrenceHandle10.1023/A:1011925132473
R. M. Fielding L. Moon-McDermott R. O. Lewis M. J. Horner (1999)ArticleTitlePharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkeyAntimicrob. Agents Chemother.43 503–509OccurrenceHandle10049258OccurrenceHandle1:CAS:528:DyaK1MXhsF2htLo%3DOccurrenceHandle10.1093/jac/43.4.503
P. R. Donald F. A. Sirgel A. Venter E. Smit D. P. Parkin B. W. WalParticleVan de D. A. Mitchison (2001)ArticleTitleThe early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosisJ. Antimicrob. Chemother.48 877–880OccurrenceHandle11733472OccurrenceHandle1:CAS:528:DC%2BD38Xjt1eitA%3D%3DOccurrenceHandle10.1093/jac/48.6.877
E. Fattal M. Youssef P. Couvreur A. Andremont (1989)ArticleTitleTreatment of experimental salmonellosis in mice with ampicillin-bound nanoparticlesAntimicrob. Agents Chemother.33 1540–1543OccurrenceHandle2684009OccurrenceHandle1:CAS:528:DyaL1MXlvVSmurk%3D
E. Fattal J. Rojas M. Youssef P. Couvreur A. Andremont (1991)ArticleTitleLiposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosisAntimicrob. Agents Chemother.35 770–772OccurrenceHandle2069386OccurrenceHandle1:CAS:528:DyaK3MXitFCgsr8%3D
E. Fattal O. Balland H. Alphandary S. Pecquet F. Puisieux P. Couvreur A. Andremont (1993) Colloidal carriers of antibiotics as an alternative approach for the treatment of intracellular infections D. Raoult (Eds) Antimicrobial Agents and Intracellular Pathogens CRC Press Boca Raton, FL 63–72
M. Yousseff E. Fattal M. J. Alonso L. Roblot-Treupel J. Sauzières C. Tancrède A. Omnes P. Couvreur A. Andremont (1988)ArticleTitleEffectiveness of nanoparticle-bound ampicillin in the treatment ofListeria monocytogenes infection in athymic nude miceAntimicrob. Agents Chemother.32 1204–1207
M. E. Page-Clisson H. Pinto-Alphandary E. Chachaty P. Couvreur A. Andremont (1998)ArticleTitleDrug targeting by polyalkylcyanoacrylate is not efficient against persistent SalmonellaPharm. Res.15 542–547
Y. Zhang (2005)ArticleTitleThe magic bullets and tuberculosis targetsAnnu. Rev. Pharmacol. Toxicol.45 529–564OccurrenceHandle15822188OccurrenceHandle1:CAS:528:DC%2BD2MXisVWjtLg%3DOccurrenceHandle10.1146/annurev.pharmtox.45.120403.100120
A. I. Vitas R. Diaz C. Gamazo (1996)ArticleTitleEffect on composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected withBrucella abortusAntimicrob. Agents Chemother.40 146–151OccurrenceHandle8787896OccurrenceHandle1:CAS:528:DyaK28XhvFOitQ%3D%3D
A. Engel S. Kumar Chatterjee A. Al-Arifi D. Riemann J. Laugner P. Nuhn (2003)ArticleTitleInfluence of spacer length in interaction of mannosylated liposomes with human phagocytic cellsPharm. Res.20 51–57OccurrenceHandle12608536OccurrenceHandle1:CAS:528:DC%2BD3sXoslKhsA%3D%3DOccurrenceHandle10.1023/A:1022294624256
K. E. Anderson L. A. Eliot B. R. Stevenson J. A. Rogers (2001)ArticleTitleFormulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage formPharm. Res.18 316–322OccurrenceHandle11442271OccurrenceHandle1:CAS:528:DC%2BD3MXltVSksbo%3DOccurrenceHandle10.1023/A:1011002913601
C. I. Price J. W. Horton C. R. Baxter (1994)ArticleTitleLiposome encapsulation: a method for enhancing the effectiveness of local antibioticsSurgery115 480–487OccurrenceHandle8165539OccurrenceHandle1:STN:280:DyaK2c3hvVOqsw%3D%3D
N. M. Sanderson M. N. Jones (1996)ArticleTitleEncapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth ofStaphylococcus epidermidisJ. Drug Target.4 181–189OccurrenceHandle8959490OccurrenceHandle1:CAS:528:DyaK28XntVGnt7c%3D
J. Frucht-Perry K. K. Assil E. Ziegler H. Douglas S. I. Brown D. J. Schanzlin R. N. Weinreb (1992)ArticleTitleFibrin-enmeshed tobramycin liposomes: single application topical therapy ofPseudomonas keratitisCornea11 393–397OccurrenceHandle1424666OccurrenceHandle1:STN:280:DyaK3s%2FkvVSjsA%3D%3D
J. Conley H. Yang T. Wilson K. Blasetti V. NinnoParticleDi G. Schnell J. Park Wong (1997)ArticleTitleAerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy againstFrancisella tularensis infection in miceAntimicrob. Agents Chemother.41 1288–1292OccurrenceHandle9174185OccurrenceHandle1:CAS:528:DyaK2sXjsFCgtL8%3D
J. P. Wong H. Yang K. L. Blasetti G. Schnell J. Conley L. N. Schofield (2003)ArticleTitleLiposome delivery of ciprofloxacin against intracellularFrancisella tularensis infectionJ. Control. Release92 265–273OccurrenceHandle14568408OccurrenceHandle1:CAS:528:DC%2BD3sXot1SrsLo%3DOccurrenceHandle10.1016/S0168-3659(03)00358-4
M. A. Rauschmann T. A. Wichelhous V. Stirnal E. Dingeldein L. Zichner R. Schnettle V. Alt (2005)ArticleTitleNanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infectionsBiomaterials26 2677–2684OccurrenceHandle15585271OccurrenceHandle1:CAS:528:DC%2BD2cXhtVChsrrKOccurrenceHandle10.1016/j.biomaterials.2004.06.045
D. Jikia N. Chkhaidze E. Imedashvili I. Mgaloblishvili G. Tsitlanadze R. Katsarava J. Glenn Morris A. Sulakvelidze (2005)ArticleTitleThe use if a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistantStaphylococcus aureus-infection local radiation injuries caused by exposure to Sr 90Clin. Exp. Dermatol.30 23–26OccurrenceHandle15663496OccurrenceHandle1:STN:280:DC%2BD2M%2Fjs12mtQ%3D%3DOccurrenceHandle10.1111/j.1365-2230.2004.01600.x
J. Wang B. Hu M. Xu Q. Yan S. Liu X. Zhu Z. Sun D. Tao L. Ding E. Reed J. Gong Q. Q. Li J. Hu (2006)ArticleTitleTherapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producingEscherichia coli bacteremiaInt. J. Mol. Med.17 347–355OccurrenceHandle16391836
J. Wang B. Hu M. Xu Q. Yan S. Liu X. Zhu Z. Sun E. Reed L. Ding J. Gong Q. Q. Li J. Hu (2006)ArticleTitleUse of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistantPseudomonas aeruginosaInt. J. Mol. Med.17 309–317OccurrenceHandle16391831
D. A. Putnam (1996)ArticleTitleAntisense strategies and therapeutic applicationsAm. J. Health-Syst. Pharm.52 151–160
N. Duzgunes E. Pretzer S. Simoes V. Slepushkin K. Konopka D. Flasher M. C. Pedroso de Lima (1999)ArticleTitleLiposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cellsMol. Membr. Biol.16 111–118OccurrenceHandle10332745OccurrenceHandle1:CAS:528:DyaK1MXis1Ggsr4%3DOccurrenceHandle10.1080/096876899294832
C. Martinand-Mari B. Lebleu I. Robbins (2003)ArticleTitleOligonucleotide-based strategies to inhibit human hepatitis C virusOligonucleotides13 348–539OccurrenceHandle10.1089/154545703322860834OccurrenceHandle1:CAS:528:DC%2BD2cXhs12kurs%3D
V. Nair (2003)ArticleTitleNovel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agentsCurr. Pharm. Des.9 2553–2565OccurrenceHandle14529542OccurrenceHandle1:CAS:528:DC%2BD3sXpsVCktL0%3DOccurrenceHandle10.2174/1381612033453703
K. Maggon S. Barik (2004)ArticleTitleNew drugs and treatment for respiratory syncytial virusRev. Med. Virol.14 149–168OccurrenceHandle15124232OccurrenceHandle1:CAS:528:DC%2BD2cXltFOlt7o%3DOccurrenceHandle10.1002/rmv.423
J. M. Irache M. Merodio A. Arnedo M. A. Camapanero M. Mirchahi S. Espuelas (2005)ArticleTitleAlbumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugsMini Rev. Med. Chem.5 293–305OccurrenceHandle15777263OccurrenceHandle1:CAS:528:DC%2BD2MXhvVCgt74%3D
M. Markosian R. M. Hyde (2005)ArticleTitleOligonucleotides and polyribonucleotides: a review of antiviral activityAntivir. Chem. Chemother.16 91–102OccurrenceHandle15889532OccurrenceHandle1:CAS:528:DC%2BD2MXktlanu78%3D
N. Duzgunes S. Simoes V. Slepushkin E. Pretzer E. ClerqParticleDe V. P. Antao M. L. Collins M. C. Pedroso de Lima (2001)ArticleTitleEnhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH sensitive liposomesNucleosides Nucleotides Nucleic Acids20 515–523OccurrenceHandle11563068OccurrenceHandle1:CAS:528:DC%2BD3MXmslCqs7Y%3DOccurrenceHandle10.1081/NCN-100002327
A. M. Harandi (2004)ArticleTitleThe potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challengesJ. Clin. Virol.30 207–210OccurrenceHandle15135735OccurrenceHandle1:CAS:528:DC%2BD2cXjvVanur8%3D
G. K. Mutwiri A. K. Nichano S. Babiuk L. A. Babiuk (2004)ArticleTitleStrategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotidesJ. Control. Release97 1–17OccurrenceHandle15147800OccurrenceHandle1:CAS:528:DC%2BD2cXjvFOntr8%3DOccurrenceHandle10.1016/j.jconrel.2004.02.022
D. Trabattoni A. Clivio D. H. Bray L. Bhagat S. Beltrami G. Maffeis R. Cesana P. Lowry F. Lissoni E. R. Kandimalla T. Sullivan S. Agrawal R. Bartholomew M. Clerici (2006)ArticleTitleImmunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in miceVaccine24 1470–1477OccurrenceHandle16221513OccurrenceHandle1:CAS:528:DC%2BD28Xhs1Smt7c%3DOccurrenceHandle10.1016/j.vaccine.2005.05.047
A. Bochot P. Couvreur E. Fattal (2000)ArticleTitleIntravitreal administration of antisense oligonucleotides: potential of liposomal deliveryProg. Retin. Eye Res.19 131–147OccurrenceHandle10674705OccurrenceHandle1:CAS:528:DC%2BD3cXhtFaruro%3DOccurrenceHandle10.1016/S1350-9462(99)00014-2
A. Arnedo J. M. Irache M. Merodio M. S. Espuelas Millan (2004)ArticleTitleAlbumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotideJ. Control. Release94 217–227OccurrenceHandle14684285OccurrenceHandle1:CAS:528:DC%2BD3sXpslClsbY%3DOccurrenceHandle10.1016/j.jconrel.2003.10.009
A. Bochot E. Fattal V. Boutet J. R. Deverre J. C. Jeanny H. Chacun P. Couvreur (2002)ArticleTitleIntravitreal delivery of oligonucleotides by sterically stabilized liposomesInvestig. Ophtalmol. Vis. Sci.43 253–259
E. Fattal G. RosaParticleDe A. Bochot (2004)ArticleTitleGel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acidsInt. J. Pharm.277 25–30OccurrenceHandle15158966OccurrenceHandle1:CAS:528:DC%2BD2cXktFOisL0%3DOccurrenceHandle10.1016/j.ijpharm.2003.01.002
F. Shi D. Hoekstra (2004)ArticleTitleEffective intracellular delivery of oligonucleotides in order to make sense of antisenseJ. Control. Release97 189–209OccurrenceHandle15196747OccurrenceHandle1:CAS:528:DC%2BD2cXkslKmtLY%3DOccurrenceHandle10.1016/j.jconrel.2004.03.016
C. Ropert M. Lavigno C. Dubernet P. Couvreur C. Malvy (1992)ArticleTitleOligonucleotides encapsulated in pH-sensitive liposomes are efficient toward Friend retrovirusBiochem. Biophys. Res. Commun.183 879–885OccurrenceHandle1550594OccurrenceHandle1:CAS:528:DyaK38XitVSqtbs%3DOccurrenceHandle10.1016/0006-291X(92)90565-3
C. Ropert C. Malvy P. Couvreur (1993)ArticleTitleInhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of actionPharm. Res.10 1427–1433OccurrenceHandle8272403OccurrenceHandle1:CAS:528:DyaK3sXmslyntLc%3DOccurrenceHandle10.1023/A:1018910922633
C. Ropert Z. MishalSuffixJr. J. M. Rodrigues C. Malvy P. Couvreur (1996)ArticleTitleRetrovirus budding may contribute a port of entry for drug carriersBiochim. Biophys. Acta1310 53–59OccurrenceHandle9244175OccurrenceHandle10.1016/0167-4889(95)00140-9
M. Berton P. Turelli D. Trono C. A. Stein E. Allemann R. Gurny (2001)ArticleTitleInhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticlesPharm. Res.18 1096–1101OccurrenceHandle11587479OccurrenceHandle1:CAS:528:DC%2BD3MXnt1ektrk%3DOccurrenceHandle10.1023/A:1010962507273
A. Zimmer (1999)ArticleTitleAntisense oligonucleotides delivery with polyhexylcyanoacrylate nanoparticles as carriersMethods18 286–295OccurrenceHandle10454987OccurrenceHandle1:CAS:528:DyaK1MXltFKkurs%3DOccurrenceHandle10.1006/meth.1999.0786
G. Lambert E. Fattal P. Couvreur (2001)ArticleTitleNanoparticulate systems for the delivery of antisense oligonucleotidesAdv. Drug Deliv. Rev.47 99–112OccurrenceHandle11251248OccurrenceHandle1:CAS:528:DC%2BD3MXhvVajsrc%3DOccurrenceHandle10.1016/S0169-409X(00)00116-2
V. Vogel D. Lochmann J. Weyermann G. Mayer C. Tziatzios J. A. BroekParticleVan den W. Haase D. Wouters U. S. Schubert J. Kreuter A. Zimmer D. Schubert (2005)ArticleTitleOligonucleotide–protamine–albumin nanoparticles: preparation, physical properties, and intracellular distributionJ. Control. Release103 99–111OccurrenceHandle15710504OccurrenceHandle1:CAS:528:DC%2BD2MXhtlequrs%3DOccurrenceHandle10.1016/j.jconrel.2004.11.029
Q. Hu C. R. Shew M. B. Bally T. D. Madden (2001)ArticleTitleProgrammable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effectsBiochim. Biophys. Acta1514 1–13OccurrenceHandle11513800OccurrenceHandle1:CAS:528:DC%2BD3MXmtFWjt7k%3DOccurrenceHandle10.1016/S0005-2736(01)00294-2
J. Kunizawa T. Masuda K. Katayama T. Yoshikawa Y. Tsutsumi M. Akashi T. Mayumi S. Nakagawa (2005)ArticleTitleFusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene releaseJ. Control. Release105 344–353OccurrenceHandle10.1016/j.jconrel.2005.03.020OccurrenceHandle1:CAS:528:DC%2BD2MXlvVyrtbw%3D
A. Dembri M. J. Montisci J. C. Gantier H. Chacun G. Ponchel (2001)ArticleTitleTargeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissuesPharm. Res.18 467–473OccurrenceHandle11451033OccurrenceHandle1:CAS:528:DC%2BD3MXkvFCnsrY%3DOccurrenceHandle10.1023/A:1011050209986
H. Boudad P. Legrand M. Appel M. H. Coconier G. Ponchel (2001)ArticleTitleFormulation and cytotoxicity of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on Caco-2 cells monolayers intended for oral administration of saquinavirSTP Pharm. Sci.11 369–375OccurrenceHandle1:CAS:528:DC%2BD38XovVKltw%3D%3D
A. R. Bender H. BriesenParticleVon J. Kreuter I. B. Duncan H. Rubasmen-Waigmann (1996)ArticleTitleEfficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophagesin vitroAntimicrob. Agents Chemother.40 1467–1471OccurrenceHandle8726020OccurrenceHandle1:CAS:528:DyaK28XjtlWmtbw%3D
F. JaeghereParticleDe E. Allemann F. Kubel B. Galli R. Cozens E. Doelker R. Gurny (2000)ArticleTitleOral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional stateJ. Control. Release68 291–298OccurrenceHandle10925137OccurrenceHandle10.1016/S0168-3659(00)00272-8
M. Meridio J. M. Irache F. Valamanesh M. Mirshahi (2002)ArticleTitleOcular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in ratsBiomaterials23 1587–1594OccurrenceHandle10.1016/S0142-9612(01)00284-8
M. Fresta G. Fontana C. Bucolo G. Cavallo G. Giammona G. Puglisi (2001)ArticleTitleOcular tolerability andin vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovirJ. Pharm. Sci.9 288–297OccurrenceHandle10.1002/1520-6017(200103)90:3<288::AID-JPS4>3.0.CO;2-5
S. C. Sookoian (2003)ArticleTitleNew therapies on the horizon for hepatitis CAnn. Hepatol.2 164–170OccurrenceHandle15115955
G. V. Papatheodorodis E. Cholongitas (2004)ArticleTitleChronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic optionsJ. Viral Hepatitis11 287–296OccurrenceHandle10.1111/j.1365-2893.2004.00522.x
M. L. Shiffman (2004)ArticleTitleRetreatment of patients who do not respond to initial therapy for chronic hepatitis CClevel. Clin. J. Med.71 S13–S16OccurrenceHandle10.3949/ccjm.71.Suppl_3.S13
M. Singh D. T. O'Hagan (2002)ArticleTitleRecent advances in vaccine adjuvantsPharm. Res.19 715–728OccurrenceHandle12134940OccurrenceHandle1:CAS:528:DC%2BD38XltVSgsLs%3DOccurrenceHandle10.1023/A:1016104910582
J. A. Berzofsky J. D. Ahlers J. Janik J. Morris S. Oh M. Tarabe I. M. Belyakov (2004)ArticleTitleProgress on new vaccine strategies against chronic viral infectionsJ. Clin. Invest.114 450–462OccurrenceHandle15314679OccurrenceHandle1:CAS:528:DC%2BD2cXmvVemu70%3DOccurrenceHandle10.1172/JCI200422674
D. T. O'Hagan R. Rappuoli (2004)ArticleTitleNovel approaches to vaccine deliveryPharm. Res.21 1519–1530OccurrenceHandle15497674OccurrenceHandle10.1023/B:PHAM.0000041443.17935.33
M. Vajdy I. Srivastava J. Polo J. Donnelly D. O'Hagan M. Singh (2004)ArticleTitleMucosal adjuvants and delivery systems for protein-,DNA- and RNA-based vaccinesImmunol. Cell Biol.82 616–627OccurrenceHandle10.1111/j.1440-1711.2004.01288.xOccurrenceHandle1:CAS:528:DC%2BD2cXhtFakur%2FP
J. Kreuter (1995)ArticleTitleNanoparticles as adjuvants for vaccinesPharm. Biotechnol.6 463–472OccurrenceHandle7551231OccurrenceHandle1:CAS:528:DyaK2MXpsFGrsrw%3D
Z. H. Jiang R. R. Koganty (2003)ArticleTitleSynthetic vaccines: the role of adjuvants in immune targetingCurr. Med. Chem.10 1423–1439OccurrenceHandle12871139OccurrenceHandle1:CAS:528:DC%2BD3sXls1Wrtbc%3DOccurrenceHandle10.2174/0929867033457340
C. Moser I. C. Metcalfe J. F. Viret (2003)ArticleTitleVirosomal adjuvanted antigen delivery systemsExpert Rev. Vaccines2 189–196OccurrenceHandle12899570OccurrenceHandle1:CAS:528:DC%2BD3sXjsVOksL4%3DOccurrenceHandle10.1586/14760584.2.2.189
L. Leserman (2004)ArticleTitleLiposomes as protein carriers in immunologyJ. Liposome Res.14 175–189OccurrenceHandle15676125OccurrenceHandle1:CAS:528:DC%2BD2cXhtVCisbjJOccurrenceHandle10.1081/LPR-200039198
M. J. Copland T. Rades N. M. Davies M. A. Baird (2005)ArticleTitleLipid based particulate formulations for the delivery of antigensImmunol. Cell Biol.83 97–105OccurrenceHandle15748206OccurrenceHandle1:CAS:528:DC%2BD2MXjsV2qsro%3DOccurrenceHandle10.1111/j.1440-1711.2005.01315.x
A. Huckriede L. Bungener T. Stegmann T. Daemen J. Medema A. M. Palache J. Wilschut (2005)ArticleTitleThe virosome concept for influenza vaccinesVaccine23S1 S1/26–S1/38
N. Westerfeld R. Zurbriggen (2005)ArticleTitlePeptides delivered by immunostimulating reconstituted influenza virosomesJ. Pept. Sci.11 707–712OccurrenceHandle16059967OccurrenceHandle1:CAS:528:DC%2BD2MXht1ehtL%2FNOccurrenceHandle10.1002/psc.700
J. Kreuter P. Speiser (1976)ArticleTitleIn vitro studies of poly(methylmethacrylate) adjuvantsJ. Pharm. Sci.65 1624–1627OccurrenceHandle993993OccurrenceHandle1:CAS:528:DyaE2sXitFOgtw%3D%3D
G. Gregoriadis (1994)ArticleTitleThe immunological adjuvant and vaccine carrier properties of liposomesJ. Drug Target.2 351–356OccurrenceHandle7704478OccurrenceHandle1:CAS:528:DyaK2MXjtVChsbc%3D
J. Aucouturier L. Dupuis V. Ganne (2001)ArticleTitleAdjuvants designed for veterinary and human vaccinesVaccine19 2666–2672OccurrenceHandle11257407OccurrenceHandle1:CAS:528:DC%2BD3MXitVOitrY%3DOccurrenceHandle10.1016/S0264-410X(00)00498-9
T. Daemen L. Bungener A. Huckriede J. Wilschut (2000)ArticleTitleVirosomes as an antigen delivery systemJ. Liposome Res.10 329–338OccurrenceHandle1:CAS:528:DC%2BD3MXlt1GktA%3D%3D
R. Glück I. C. Metcalfe (2002)ArticleTitleNew technology platforms in the development of vaccines for the futureVaccine20 B10–B16OccurrenceHandle12477412OccurrenceHandle10.1016/S0264-410X(02)00513-3
S. Esposito P. Marchisio S. Bosis L. Lambertini L. Claut N. Faelli C. Bianchi G. L. Colombo N. Principi (2006)ArticleTitleClinical and economic impact of influenza vaccination on healthy children aged 2–5 yearsVaccine24 629–635OccurrenceHandle16157429OccurrenceHandle10.1016/j.vaccine.2006.03.059
R. Noad P. Roy (2003)ArticleTitleVirus-like particles as immunogensTrends Microbiol.11 438–444OccurrenceHandle13678860OccurrenceHandle1:CAS:528:DC%2BD3sXnt1ylu70%3DOccurrenceHandle10.1016/S0966-842X(03)00208-7
R. L. Garcea L. Gissmann (2004)ArticleTitleVirus-like particles as vaccines and vessels for the delivery of small moleculesCurr. Opin. Biotechnol.15 513–517OccurrenceHandle15560977OccurrenceHandle1:CAS:528:DC%2BD2cXhtVWjtrzMOccurrenceHandle10.1016/j.copbio.2004.10.002
T. Storni C. Ruedl K. Schwarz R. A. Schwendener W. A. Renner M. F. Bachmann (2004)ArticleTitleNonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effectsJ. Immunol.172 1777–1785OccurrenceHandle14734761OccurrenceHandle1:CAS:528:DC%2BD2cXptl2hsg%3D%3D
B. Morein K. F. Hu I. Abusugra (2004)ArticleTitleCurrent status and potential application of ISCOMs in veterinary medicineAdv. Drug Deliv. Rev.56 1367–1382OccurrenceHandle15191787OccurrenceHandle1:CAS:528:DC%2BD2cXkvVCrt7g%3DOccurrenceHandle10.1016/j.addr.2004.02.004
P. HoegenParticleVon (2001)ArticleTitleSynthetic biomimetic supra molecular Biovector™ (SMBV™) particles for nasal vaccine deliveryAdv. Drug Deliv. Rev.51 113–125OccurrenceHandle10.1016/S0169-409X(01)00175-2
A. Debin R. Kravtzoff J. SantiagoParticleVaz L. Cazales S. Sperandio K. Melber Z. Janowicz D. Betbeder M. Moynier (2002)ArticleTitleIntranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responsesVaccine20 2752–2763OccurrenceHandle12034102OccurrenceHandle1:CAS:528:DC%2BD38XktVCrtbc%3DOccurrenceHandle10.1016/S0264-410X(02)00191-3
B. C. Baudner O. Balland M. M. Guiliani P. HoegenParticleVon R. Rappuoli D. Betbeder G. GiudiceParticleDel (2002)ArticleTitleEnhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered nanoparticlesInfect. Immun.70 4785–4790OccurrenceHandle12183520OccurrenceHandle1:CAS:528:DC%2BD38Xmtl2itb0%3DOccurrenceHandle10.1128/IAI.70.9.4785-4790.2002
T. Jung W. Kamm A. Breitenbach K. D. Hungerer E. Hundt T. Kissel (2001)ArticleTitleTetanus toxoid loaded nanoparticles from sulfobutylated poly(vinylalcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in micePharm. Res.18 352–360OccurrenceHandle11442276OccurrenceHandle1:CAS:528:DC%2BD3MXltVSksbc%3DOccurrenceHandle10.1023/A:1011063232257
M. Conacher J. Alexander J. M. Brewer (2001)ArticleTitleOral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)Vaccine19 2965–2974OccurrenceHandle11282208OccurrenceHandle1:CAS:528:DC%2BD3MXit1Wgtb0%3DOccurrenceHandle10.1016/S0264-410X(00)00537-5
R. Gluck (2002)ArticleTitleIntranasal immunization against influenzaJ. Aerosol Med.15 221–218OccurrenceHandle12184872OccurrenceHandle10.1089/089426802320282347
J. Holmgren C. Czerkinsky K. Erikssen A. Mharandi (2003)ArticleTitleMucosal immunisation and adjuvants: a brief overview of recent advances and challengesVaccine21IssueID(Suppl 2) S89–S95OccurrenceHandle12763689OccurrenceHandle10.1016/S0264-410X(03)00206-8OccurrenceHandle1:CAS:528:DC%2BD3sXjvFWls7w%3D
J. Panyam V. Labhasetwar (2003)ArticleTitleBiodegradable nanoparticles for drug and gene delivery to cells and tissueAdv. Drug Deliv. Rev.55 329–347OccurrenceHandle12628320OccurrenceHandle1:CAS:528:DC%2BD3sXhs1Cgurw%3DOccurrenceHandle10.1016/S0169-409X(02)00228-4
M. Koping-Hoggard A. Sanchez M. J. Alonso (2005)ArticleTitleNanoparticles as carriers for nasal vaccine deliveryExpert Rev. Vaccines4 185–196OccurrenceHandle15889992OccurrenceHandle10.1586/14760584.4.2.185OccurrenceHandle1:CAS:528:DC%2BD2MXjt1yls7w%3D
A. T. Florence (1997)ArticleTitleThe oral absorption of micro- and nanoparticulates: neither exceptional nor unusualPharm. Res.14 259–266OccurrenceHandle9098866OccurrenceHandle1:CAS:528:DyaK2sXisVGlsro%3DOccurrenceHandle10.1023/A:1012029517394
S. Mcclean F. Prosser F. Meehan D. O'Malley N. Clarke Z. Ramtoola D. Brayden (1998)ArticleTitleBinding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epitheliaEur. J. Pharm. Sci.6 153–163OccurrenceHandle9795038OccurrenceHandle1:CAS:528:DyaK1cXhsFejt7s%3DOccurrenceHandle10.1016/S0928-0987(97)10007-0
T. Jung W. Kamm A. Breitenbach E. Kaiserling J. X. Xiao T. Kissel (2000)ArticleTitleBiodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?Eur. J. Pharm. Biopharm.50 147–160OccurrenceHandle10840198OccurrenceHandle1:CAS:528:DC%2BD3cXjslyisrs%3DOccurrenceHandle10.1016/S0939-6411(00)00084-9
E. Fattal S. Pecquet P. Couvreur A. Andremont (2002)ArticleTitleBiodegradable microparticles for the mucosal delivery of antibacterial and dietary antigensInt. J. Pharm.242 15–24OccurrenceHandle12176221OccurrenceHandle1:CAS:528:DC%2BD38Xmt1ygur4%3DOccurrenceHandle10.1016/S0378-5173(02)00181-3
M. Shakweh M. Besnard V. Nicolas E. Fattal (2005)ArticleTitlePoly(lactide-co-glycolide) particles of different physicochemical properties and their uptake by Peyer's patches in miceEur. J. Pharm. Biopharm.61 1–13OccurrenceHandle16005619OccurrenceHandle1:CAS:528:DC%2BD2MXntVGjs7Y%3DOccurrenceHandle10.1016/j.ejpb.2005.04.006
T. Fifis A. Gamvrellis B. Crimeen-Irwin G. A. Pietersz J. Li P. L. Mottram I. F. McKenzie M. Plebanski (2004)ArticleTitleSize-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumorsJ. Immunol.173 3148–3154OccurrenceHandle15322175OccurrenceHandle1:CAS:528:DC%2BD2cXmvVCqtrs%3D
J. F. Mann V. A. Ferro A. B. Mullen L. Tetley M. Mullen K. C. Carter J. Alexander W. H. Stimson (2004)ArticleTitleOptimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutininVaccine22 2425–2429OccurrenceHandle15193405OccurrenceHandle1:CAS:528:DC%2BD2cXkvVemt7w%3DOccurrenceHandle10.1016/j.vaccine.2003.11.067
U. Gluck J. O. Gebbers R. Gluck (1999)ArticleTitlePhase 1 evaluation of intranasal virosomal influenza vaccine with and withoutEscherichia coli heat-labile toxin in adult volunteersJ. Virol.73 7780–7786OccurrenceHandle10438868OccurrenceHandle1:CAS:528:DyaK1MXltlKhur0%3D
M. Mutsch W. Zhou P. Rhodes M. Bopp R. T. Chen T. Linder C. Spyr R. Steffen (2004)ArticleTitleUse of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in SwitzerlandN. Engl. J. Med.350 896–903OccurrenceHandle14985487OccurrenceHandle1:CAS:528:DC%2BD2cXhsFygsbY%3DOccurrenceHandle10.1056/NEJMoa030595
J. A. Berzofsky J. D. Ahlers I. M. Belyakov (2001)ArticleTitleStrategies for designing and optimizing new generation vaccinesNat. Rev. Immunol.1 209–219OccurrenceHandle11905830OccurrenceHandle1:CAS:528:DC%2BD38XmtVSjs70%3DOccurrenceHandle10.1038/35105075
M. Diwan P. Elamanchili H. Lane A. Gainer J. Samuel (2003)ArticleTitleBiodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responsesJ. Drug Target.11 495–507OccurrenceHandle15203918OccurrenceHandle1:CAS:528:DC%2BD2cXjt1Crs78%3DOccurrenceHandle10.1080/10611860410001670026
X. Jiao R. Y. Wang Q. Qiu H. J. Alter J. W. Shih (2004)ArticleTitleEnhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomesJ. Gen. Virol.85 1545–1553OccurrenceHandle15166438OccurrenceHandle1:CAS:528:DC%2BD2cXltlGhtro%3DOccurrenceHandle10.1099/vir.0.79896-0
M. Kerkmann C. L. Costa C. Richter S. Rothenfusser J. Battiany V. Hornung J. Johnson S. Englert T. Ketterer W. Heckl S. Thalhammer S. Endres G. Hartmann (2005)ArticleTitleSpontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cellsJ. Biol. Chem.280 8086–8093OccurrenceHandle15591070OccurrenceHandle1:CAS:528:DC%2BD2MXhs1yitbg%3DOccurrenceHandle10.1074/jbc.M410868200
S. Manoj L. A. Babiuk V. Drunen Littel-van den HurkParticlevan (2004)ArticleTitleApproaches to enhance the efficacy of DNA vaccinesCrit. Rev. Clin. Lab. Sci.41 1–39OccurrenceHandle15077722OccurrenceHandle1:CAS:528:DC%2BD2cXivVCjs7k%3DOccurrenceHandle10.1080/10408360490269251
Z. Cui R. J. Mumper (2002)ArticleTitleGenetic immunization using nanoparticles engineered from microemulsion precursorPharm. Res.19 939–946OccurrenceHandle12180545OccurrenceHandle1:CAS:528:DC%2BD38Xltl2is7c%3DOccurrenceHandle10.1023/A:1016402019380
H. Q. Mao K. Roy V. L. Troung-La K. A. Janes K. Y. Lin Y. Wang J. T. August K. W. Leong (2001)ArticleTitleChitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiencyJ. Control. Release70 399–421OccurrenceHandle11182210OccurrenceHandle1:CAS:528:DC%2BD3MXhtV2murs%3DOccurrenceHandle10.1016/S0168-3659(00)00361-8
M. Bivas-Benita T. H. Ottenhoff H. E. Junginger G. Borchard (2005)ArticleTitlePulmonary DNA vaccination: concepts, possibilities and perspectivesJ. Control. Release107 1–29OccurrenceHandle16054263OccurrenceHandle1:CAS:528:DC%2BD2MXpvVSgu7g%3DOccurrenceHandle10.1016/j.jconrel.2005.05.028
C. P. Locher D. Putnam R. Langer S. A. Witt B. M. Ashlock J. A. Levy (2003)ArticleTitleEnhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulationImmunol. Lett.90 67–70OccurrenceHandle14687705OccurrenceHandle1:CAS:528:DC%2BD3sXpvVWqu7c%3DOccurrenceHandle10.1016/j.imlet.2003.02.001
Z. Cui S. J. Han D. Padinjarae Vangasseri L. Huang (2005)ArticleTitleImmunostimulation mechanism of LPD nanoparticle as a vaccine carrierMol. Pharmacol.2IssueID(1) 22–28OccurrenceHandle1:CAS:528:DC%2BD2cXhtVOjt7vN
B. Verrier (2005)ArticleTitleTherapeutic vaccination for chronic infectious diseases: lessons from HIV-1J. Clin. Virol.34 S9–S12OccurrenceHandle16461232OccurrenceHandle1:CAS:528:DC%2BD28XhtlGmsr0%3DOccurrenceHandle10.1016/S1386-6532(05)80003-4
M. L. Michel M. Mancini-Bourgine (2005)ArticleTitleTherapeutic vaccination against chronic hepatitis B virus infectionJ. Clin. Virol.34 S108–S114OccurrenceHandle16461209OccurrenceHandle1:CAS:528:DC%2BD28XhtlGnuro%3DOccurrenceHandle10.1016/S1386-6532(05)80019-8
World Health Organisation. Diabetes,http://www.who.int/mediacentre/factsheets/fs138/en/index.html, (accessed Nov 15, 2005) part ofhttp://www.who.int (accessed Nov 15, 2005).
S. I. Tanaka T. Yamakawa I. Aoki K. Okuda C. Mobbs (2004)ArticleTitleDaily nasal inoculation with the insulin gene ameliorates diabetes in miceDiabetes Res. Clin. Pract.63 1–9OccurrenceHandle14693407OccurrenceHandle1:CAS:528:DC%2BD3sXpvF2msbw%3DOccurrenceHandle10.1016/j.diabres.2003.07.005
F. Gomez-Perez J. A. Rull (2005)ArticleTitleInsulin therapy: current alternativesArch. Med. Res.36 258–72OccurrenceHandle15925016OccurrenceHandle1:CAS:528:DC%2BD2MXks1Cnurg%3DOccurrenceHandle10.1016/j.arcmed.2005.03.012
M. Muno-Torres G. Alonso M. P. Raya (2004)ArticleTitleCalcitonin therapy in osteoporosisTreat. Endocrinol.3 117–132OccurrenceHandle10.2165/00024677-200403020-00006
C. Prego M. Garcia D. Torres M. J. Alonso (2005)ArticleTitleTransmucosal macromolecular drug deliveryJ. Control. Release101 151–162OccurrenceHandle15588901OccurrenceHandle1:CAS:528:DC%2BD2cXhtVKgu7bJOccurrenceHandle10.1016/j.jconrel.2004.07.030
Y. Cao L. Lam (2002)ArticleTitleProjections for insulin treatment for diabeticsDrugs Today38 419–427OccurrenceHandle1:CAS:528:DC%2BD38XlvVKnurs%3DOccurrenceHandle10.1358/dot.2002.38.6.678349OccurrenceHandle12532178
M. Saffran B. Pansky G. Colin Budd F. E Williams (1997)ArticleTitleInsulin and the gastrointestinal tractJ. Control. Release46 89–98OccurrenceHandle1:CAS:528:DyaK2sXhtlyhsLo%3DOccurrenceHandle10.1016/S0168-3659(96)01578-7
G. Dapergolas G. Gregoriadis (1976)ArticleTitleHypoglycemic effect of liposome-entrapped insulin administered intragastrically into ratsLancet2 824–827OccurrenceHandle61498OccurrenceHandle1:CAS:528:DyaE2sXkvV0%3DOccurrenceHandle10.1016/S0140-6736(76)91209-5
H. M. Patel B. E. Ryman (1976)ArticleTitleOral administration if insulin by encapsulation in liposomesFEBS Lett.62 60–63OccurrenceHandle129340OccurrenceHandle1:CAS:528:DyaE28XhtlSks74%3DOccurrenceHandle10.1016/0014-5793(76)80016-6
J. F. Woodley (1985)ArticleTitleLiposomes for oral administration of drugsCrit. Rev. Ther. Drug Carr. Syst.2 1–18OccurrenceHandle1:CAS:528:DyaL28XhtFGqsrw%3D
C. Damgé C. Michel M. Aprahamian P. Couvreur (1988)ArticleTitleNew approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrierDiabetes37 246–251OccurrenceHandle3292320
R. S. Spangler (1990)ArticleTitleInsulin administration via liposomesDiabetes Care13 911–922OccurrenceHandle2226109OccurrenceHandle1:STN:280:DyaK3M%2FjtV2jtA%3D%3D
G. P. Carino E. Mathiowitz (1999)ArticleTitleOral insulin deliveryAdv. Drug Deliv. Rev.35 249–257OccurrenceHandle10837700OccurrenceHandle1:CAS:528:DyaK1MXksFehuw%3D%3DOccurrenceHandle10.1016/S0169-409X(98)00075-1
C. Vauthier M. Seiller C. Weingarten P. Couvreur (1999)ArticleTitleContribution to the development of oral dosage form for insulin deliverySTP Pharm. Sci.9 391–396OccurrenceHandle1:CAS:528:DC%2BD3cXjsFyqug%3D%3D
M. A. Kisel L. N. Kulik I. S. Tsybovsky A. P. Vlasov M. S. Vorob'yov E. A. Kholodava Z. V. Zabarovskaca (2001)ArticleTitleLiposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the ratInt. J. Pharm.216 105–114OccurrenceHandle11274812OccurrenceHandle1:CAS:528:DC%2BD3MXitFyru7k%3DOccurrenceHandle10.1016/S0378-5173(01)00579-8
P. Couvreur G. Barratt E. Fattal P. Legrand C. Vauthier (2002)ArticleTitleNanocapsule technology: a reviewCrit. Rev. Ther. Drug Carr. Syst.19 99–134OccurrenceHandle1:CAS:528:DC%2BD38XntFSksbg%3DOccurrenceHandle10.1615/CritRevTherDrugCarrierSyst.v19.i2.10
S. Watnasirichaikul T. Rades I. G. Tucker N. W. Davies (2002)ArticleTitleIn-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsionJ. Pharm. Pharmacol.54 473–480OccurrenceHandle11999123OccurrenceHandle1:CAS:528:DC%2BD38XjtlWgur8%3DOccurrenceHandle10.1211/0022357021778736
K. Katayama Y. Kato H. Onishi T. Nagai Y. Machida (2003)ArticleTitleDouble liposomes: hypoglycemic effects of liposomal insulin on normal ratsDrug Dev. Ind. Pharm.29 725–731OccurrenceHandle12906329OccurrenceHandle1:CAS:528:DC%2BD3sXltlGmtbw%3DOccurrenceHandle10.1081/DDC-120021771
N. Csaba L. Gonzalez A. Sanchez M. J. Alonso (2004)ArticleTitleDesign and characterisation of new nanoparticulate polymer blends for drug deliveryJ. Biomater. Sci. Polym. Ed.15 1137–1151OccurrenceHandle15503631OccurrenceHandle1:CAS:528:DC%2BD2cXptFahurw%3DOccurrenceHandle10.1163/1568562041753098
M. Simon M. Wittmar T. Kissel T. Linn (2005)ArticleTitleInsulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(l-lactide): bioavailability and nasal tolerability in ratsPharm. Res.22 1879–1886OccurrenceHandle16132341OccurrenceHandle1:CAS:528:DC%2BD2MXhtFChs7bMOccurrenceHandle10.1007/s11095-005-7676-z
S. Mao O. Germerhaus D. Fischer T. Linn R. Schnepf T. Kissel (2005)ArticleTitleUptake and transport of PEG-graft-trimethyl-chitosan copolymer–insulin nanocomplexes by epithelias cellsPharm. Res.22 2058–2068OccurrenceHandle16170693OccurrenceHandle1:CAS:528:DC%2BD2MXhtlemtbnMOccurrenceHandle10.1007/s11095-005-8175-y
M. Garcia-Fuentes D. Torres M. J. Alonso (2005)ArticleTitleNew surface modified lipid nanoparticles as delivery vehicle for salmon calcitoninInt. J. Pharm.296 122–132OccurrenceHandle15885464OccurrenceHandle1:CAS:528:DC%2BD2MXktVais74%3DOccurrenceHandle10.1016/j.ijpharm.2004.12.030
N. Zhang Q. N. Ping G. H. Huang W. F. Xu (2005)ArticleTitleInvestigation of lectin-modified insulin liposomes as carriers for oral administrationInt. J. Pharm.294 247–259OccurrenceHandle15814248OccurrenceHandle1:CAS:528:DC%2BD2MXjt1agsrs%3DOccurrenceHandle10.1016/j.ijpharm.2005.01.018
M. Aprahamian C. Michel W. Humbert J. P. Devissaguet C. Damgé (1987)ArticleTitleTransmucosal passage of poly(alkylcyanoacrylate) nanocapsules as a new drug carrier in the small intestineBiol. Cell61 69–76OccurrenceHandle2833966OccurrenceHandle1:CAS:528:DyaL1cXhsFKgtL0%3D
H. Pinto-Alphandary M. Aboubakar D. Jaillard P. Couvreur C. Vauthier (2003)ArticleTitleVisualization of insulin-loaded nanocapsules:in vitro andin vivo studies after oral administration to ratsPharm. Res.20 1071–1084OccurrenceHandle12880294OccurrenceHandle1:CAS:528:DC%2BD3sXkvFSksr4%3DOccurrenceHandle10.1023/A:1024470508758
A. T. Florence (2004)ArticleTitleIssues in oral nanoparticle drug carrier uptake and targetingJ. Drug Target.12 65–70OccurrenceHandle15203899OccurrenceHandle1:CAS:528:DC%2BD2cXktVCqtbo%3DOccurrenceHandle10.1080/10611860410001693706
P. Couvreur V. Lenaerts B. Kante M. Roland P. Speiser (1980)ArticleTitleOral and parenteral administration of insulin associated to hydrolysable nanoparticlesActa Pharm. Technol.26 220
C. Damgé H. Vranckx P. Balschmidt P. Couvreur (1997)ArticleTitlePoly(alkyl cyanoacrylate) nanospheres for oral administration of insulinJ. Pharm. Sci.86 1403–1409OccurrenceHandle9423155OccurrenceHandle10.1021/js970124i
M. S. Mesiha M. B. Sidhom B. Fasipe (2005)ArticleTitleOral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticlesInt. J. Pharm.288 289–293OccurrenceHandle15620869OccurrenceHandle1:CAS:528:DC%2BD2cXhtFGhurvOOccurrenceHandle10.1016/j.ijpharm.2004.10.003
C. Damgé D. Hillaire-buys R. Puech A. Hilozel C. Michel G. Ribes (1995)ArticleTitleEffect of orally administered insulin nanocapsules in normal and diabetic ratsDiab. Nutr. Metab.8 3–9
P. J. Lowe C. S. Temple (1994)ArticleTitleCalcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in ratsJ. Pharm. Pharmacol.46 547–552OccurrenceHandle7996380OccurrenceHandle1:CAS:528:DyaK2cXlsVWntLs%3D
M. Aboubakar P. Couvreur H. Pinto-Alphandary B. Gouritin B. Lacour R. Farinotti F. Puisieux C. Vauthier (2000)ArticleTitleInsulin-loaded nanocapsules for oral administration;in vitro andin vivo investigationDrug Dev. Res.49 109–117OccurrenceHandle1:CAS:528:DC%2BD3cXislKis7g%3DOccurrenceHandle10.1002/(SICI)1098-2299(200002)49:2<109::AID-DDR4>3.0.CO;2-#
F. Cournarie D. Auchère D. Chevenne B. Lacour M. Seiller C. Vauthier (2002)ArticleTitleAbsorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic ratsInt. J. Pharm.242 325–328OccurrenceHandle12176272OccurrenceHandle1:CAS:528:DC%2BD38Xmt1ynsb8%3DOccurrenceHandle10.1016/S0378-5173(02)00175-8
G. P. Carino J. S. Jacob E. Mathiowitz (2000)ArticleTitleNanosphere based oral insulin deliveryJ. Control. Release65 261–269OccurrenceHandle10699286OccurrenceHandle1:CAS:528:DC%2BD3cXhtl2qsL0%3DOccurrenceHandle10.1016/S0168-3659(99)00247-3
S. Sakuma M. Hayashi M. Akashi (2001)ArticleTitleDesign of nanoparticles composed of graft copolymers for oral peptide deliveryAdv. Drug Deliv. Rev.47 21–37OccurrenceHandle11251243OccurrenceHandle1:CAS:528:DC%2BD3MXhvVajsro%3DOccurrenceHandle10.1016/S0169-409X(00)00119-8
C. O. Sullivan C. Birkinshaw (2004)ArticleTitleIn vitro degradation of insulin-loaded poly(n-butylcyanoacrylate) nanoparticlesBiomaterials25 4375–4382OccurrenceHandle15046928OccurrenceHandle1:CAS:528:DC%2BD2cXitlWqt7w%3DOccurrenceHandle10.1016/j.biomaterials.2003.11.001
A. Vila A. Sanchez M. Tobio P. Calvo M. J. Alonso (2002)ArticleTitleDesign of biodegradable particles for protein deliveryJ. Control. Release78 15–24OccurrenceHandle11772445OccurrenceHandle1:CAS:528:DC%2BD3MXptlaisb8%3DOccurrenceHandle10.1016/S0168-3659(01)00486-2
A. M. Hillery P. U. Jani A. T. Florence (1994)ArticleTitleComparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particlesJ. Drug Target.2 151–156OccurrenceHandle8069593OccurrenceHandle1:STN:280:DyaK2czkvVygsg%3D%3D
E. Mathiowitz J. S. Jacob Y. S. Jong G. P. Carino D. E. Chickering P. Chaturvedi C. A. Santos K. Vijayaraghavan S. Montgomery S. Bassett C. Morrell (1997)ArticleTitleBiologically erodable microspheres as potential oral drug delivery systemsNature386 410–414OccurrenceHandle9121559OccurrenceHandle1:CAS:528:DyaK2sXit1Wrt7s%3DOccurrenceHandle10.1038/386410a0
F. Delie (1998)ArticleTitleEvaluation of nano- and microparticle uptake by the gastrointestinal tractAdv. Drug Deliv. Rev.34 221–233OccurrenceHandle10837679OccurrenceHandle1:CAS:528:DyaK1cXnsFWlt7w%3DOccurrenceHandle10.1016/S0169-409X(98)00041-6
L. Behrens A. I. PenaParticleVila M. J. Alonso T. Kissel (2002)ArticleTitleComparative uptake studies of bioadhesive and non bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transportPharm. Res.19 1185–1193OccurrenceHandle12240945OccurrenceHandle1:CAS:528:DC%2BD38XmtlGgs7g%3DOccurrenceHandle10.1023/A:1019854327540
Z. Degim N. Unal D. Essiz U. Abbasoglu (2004)ArticleTitleThe effect of various liposome formulations on insulin penetration across Caco-2 cell monolayerLife Sci.75 2819–2827OccurrenceHandle15464833OccurrenceHandle1:CAS:528:DC%2BD2cXotFCmur4%3DOccurrenceHandle10.1016/j.lfs.2004.05.027
G. Ponchel J. Irache (1998)ArticleTitleSpecific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tractAdv. Drug Deliv. Rev.34 191–219OccurrenceHandle10837678OccurrenceHandle1:CAS:528:DyaK1cXnsFWlt78%3DOccurrenceHandle10.1016/S0169-409X(98)00040-4
S. P. Clissold A. Fitton P. Chrisp (1991)ArticleTitleIntranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with agingDrugs Aging1 405–423OccurrenceHandle1794028OccurrenceHandle1:STN:280:DyaK387ntlCmsg%3D%3D
S. Turker E. Onur Y. Ozer (2004)ArticleTitleNasal route and drug delivery systemsPharm. World Sci.26 137–142OccurrenceHandle15230360OccurrenceHandle10.1023/B:PHAR.0000026823.82950.ff
R. Fernandez-Urrusuno P. Calvo C. Rumunan-Lopez J. L. Vila-Lato M. J. Alonso (1999)ArticleTitleEnhancement of nasal absorption of insulin using chitosan nanoparticlesPharm. Res.16 1576–1581OccurrenceHandle10554100OccurrenceHandle1:CAS:528:DyaK1MXntVOhur4%3DOccurrenceHandle10.1023/A:1018908705446
A. Vila H. Gill O. McCallion M. J. Alonso (2004)ArticleTitleTransport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating densityJ. Control. Release98 231–244OccurrenceHandle15262415OccurrenceHandle1:CAS:528:DC%2BD2cXlslGis7Y%3DOccurrenceHandle10.1016/j.jconrel.2004.04.026
M. Simon M. Wittmar T. Kissel T. Linn (2005)ArticleTitleInsulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(l-lactide): bioavailability and nasal tolerability in ratsPharm. Res.22 1879–1886OccurrenceHandle16132341OccurrenceHandle1:CAS:528:DC%2BD2MXhtFChs7bMOccurrenceHandle10.1007/s11095-005-7676-z
C. Vermehren, S. Frokjaer, T. Aurstad, and J. Hansen. Lung surfactant as a drug delivery system.Int. J. Pharm.307:89–92 (2006).
Y. Li A. K. Mitra (1996)ArticleTitleEffects of phospholipid chain length, concentration, charge and vesicle size on pulmonary insulin absorptionPharm. Res.13 76–79OccurrenceHandle8668683OccurrenceHandle1:CAS:528:DyaK28XhtFajsr8%3DOccurrenceHandle10.1023/A:1016029317299
J. Blanchard J. Coleman C. D'Abreu Hayling R. Ghaderi B. Haeberlin J. Hart S. Jensen R. Malcolmson S. Mittelman L. M. Nagao S. Sekulic C. Snodgrass-Pilla M. Sundahl G. Thompson R. Wolff (2004)ArticleTitleForeign particles testing in orally inhaled and nasal drug productsPharm. Res.21 2137–2147OccurrenceHandle15648243OccurrenceHandle1:CAS:528:DC%2BD2MXjslOqsg%3D%3DOccurrenceHandle10.1007/s11095-004-7665-7
G. L. Wilson E. H. Leiter (1990)ArticleTitleStreptozotocin interactions with pancreatic beta cells and the induction of insulin-dependent diabetesCurr. Top. Microbiol. Immunol.156 27–54OccurrenceHandle2143132OccurrenceHandle1:STN:280:DyaK3czjs1eqtQ%3D%3D
O. Blondel B. Portha (1989)ArticleTitleEarly appearance ofin vivo insulin resistance in adult streptozotocin-injected ratsDiab. Metab.15 382–387OccurrenceHandle1:CAS:528:DyaK3MXkt1Oh
J. P. Mordes R. Cortell E. P. Clanjenhorn A. A. Rossini D. L. Greiner (2004)ArticleTitleRat models of type 1 diabetes: genetics, environment, and autoimmunityILAR J.45 278–291OccurrenceHandle15229375OccurrenceHandle1:CAS:528:DC%2BD2cXkvVyjsro%3D
N. Ubrich C. Schmidt R. Bodmeier M. Hoffman P. Maincent (2005)ArticleTitleOral evaluation in rabbits of cyclosporin-loaded Eudragit RS and RL nanoparticlesInt. J. Pharm.2888 168–175
J. K. Milani U. Pleyer A. Dukes H. J. Chou S. Lutz D. Ruckert K. H. Schmidt B. J. Mondino (1993)ArticleTitleProlongation of corneal allograft survival with liposome-encapsulated cyclosporin in the rat eyeOphthalmology100 890–896OccurrenceHandle8510902OccurrenceHandle1:STN:280:DyaK3s3ovVeltA%3D%3D
A. M. CamposParticleDe A. Sanchez M. J. Alonso (2001)ArticleTitleChitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin AInt. J. Pharm.224 159–168OccurrenceHandle11472825OccurrenceHandle10.1016/S0378-5173(01)00760-8
F. Lallemand O. Felt-Baeyens K. Bessenghir F. Behar-Cohen R. Gurny (2003)ArticleTitleCyclosporin A delivery to the eye: a pharmaceutical challengeEur. J. Pharm. Biopharm.56 307–318OccurrenceHandle14602172OccurrenceHandle1:CAS:528:DC%2BD3sXos12qtb0%3DOccurrenceHandle10.1016/S0939-6411(03)00138-3
M. G. Qaddoumi H. Ueda J. Yang J. Dvada V. Labhasetwar V. H. Lee (2004)ArticleTitleThe characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layersPharm. Res.21 641–648OccurrenceHandle15139521OccurrenceHandle1:CAS:528:DC%2BD2cXjsVWqs7s%3DOccurrenceHandle10.1023/B:PHAM.0000022411.47059.76
M. Schwartz (2001)ArticleTitleHarnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disordersCell Mol. Neurobiol.21 617–627OccurrenceHandle12043837OccurrenceHandle1:CAS:528:DC%2BD38XkslSktL4%3DOccurrenceHandle10.1023/A:1015139718466
J. Schmidt J. M. Metselaar M. H. Wauben K. V. Toyka G. Storm R. Gold (2003)ArticleTitleDrug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosisBrain126 1895–1904OccurrenceHandle12805101OccurrenceHandle10.1093/brain/awg176
Y. KozacParticleDe K. Andrieux H. Villarroya C. Klein B. Thillaye-Goldenberg M. C. Naud E. Garcia P. Couvreur (2004)ArticleTitleIntraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitisEur. J. Immunol.34 3702–3712OccurrenceHandle10.1002/eji.200425022OccurrenceHandle1:CAS:528:DC%2BD2cXhtFajtrvE
M. Schwartz (2004)ArticleTitleVaccination for glaucoma: dream or reality?Brain Res. Bull.62 481–484OccurrenceHandle15036561OccurrenceHandle1:CAS:528:DC%2BD2cXhsVOlu7o%3DOccurrenceHandle10.1016/S0361-9230(03)00073-X
C. Billotey C. Aspord O. Beuf E. Piaggio F. Gazeau M. F. Janier C. Thivolet (2005)ArticleTitleT-cell homing to the pancreas in autoimmune mouse models of diabetes:in vivo MR imagingRadiology236 579–587OccurrenceHandle15972338
C. Vauthier E. Fattal D. Labarre (2004) From polymer chemistry and physicochemistry to nanoparticulate drug carrier design and applications M. J. Yaszemski D. J. Trantolo K. U. Lewamdrowski V. Hasirci D. E. Altobelli D. L. Wise (Eds) Biomaterial Handbook—Advanced Applications of Basic Sciences and Bioengineering Marcel Dekker, Inc. New York, USA 563–598
N. Ammoury H. Fessi J. P. Devissaguet M. Dubrasquet S. Benita (1991)ArticleTitleJejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(d,l-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in ratsPharm. Res.8 101–105OccurrenceHandle2014197OccurrenceHandle1:CAS:528:DyaK3MXovVGltg%3D%3DOccurrenceHandle10.1023/A:1015846810474
F. Fawaz F. Bonini M. Guyot A. M. Lagueny H. Fessi J. P. Devissaguet (1993)ArticleTitleInfluence of poly(dl-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbitPharm. Res.10 750–756OccurrenceHandle8321841OccurrenceHandle1:CAS:528:DyaK3sXkvVSjtLw%3DOccurrenceHandle10.1023/A:1018924219540
S. S. Guterres H. Fessi G. Barratt F. Puisieux J. P. Devissaguet (1995)ArticleTitlePoly(d,l-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administrationPharm. Res.12 1545–1547OccurrenceHandle8584497OccurrenceHandle1:CAS:528:DyaK2MXosleqsrs%3DOccurrenceHandle10.1023/A:1016208125979
J. Al-Muhammed A. Y. Ozer M. T. Ercan A. A. Hincal (1996)ArticleTitleIn-vivo studies on dexamethasone sodium phosphate liposomesJ. Microencapsul.13 293–306OccurrenceHandle8860685OccurrenceHandle1:CAS:528:DyaK28XivV2htr8%3D
S. S. Guterres H. Fessi G. Barratt F. Puisieux J. P. Devissaguet (2000)ArticleTitlePoly(rac-lactide) nanocapsules containing diclofenac: protection against muscular damage in ratsJ. Biomater. Sci., Polym. Ed.11 1347–1355OccurrenceHandle1:CAS:528:DC%2BD3MXitVKrs7w%3DOccurrenceHandle10.1163/156856200744372
P. Calvo M. J. Alonso J. L. Vila-Jato J. R. Robinson (1996)ArticleTitleImproved ocular bioavailability of indomethacin by novel ocular drug carriersJ. Pharm. Pharmacol.48 1147–1152OccurrenceHandle8961163OccurrenceHandle1:CAS:528:DyaK28XnsFKjtbw%3D
C. Bucolo A. Maltese G. Plugisi R. Pignatello (2002)ArticleTitleEnhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspensionOphthalmic Res.34 319–323OccurrenceHandle12381895OccurrenceHandle1:CAS:528:DC%2BD38XnvV2rs7w%3DOccurrenceHandle10.1159/000065608
B. Jiang L. Hu C. Gao J. Shen (2005)ArticleTitleIbuprofen-loaded nanoparticles prepared by a co-precipitation method and their release propertiesInt. J. Pharm.304 220–230OccurrenceHandle16182477OccurrenceHandle1:CAS:528:DC%2BD2MXhtFSitLnEOccurrenceHandle10.1016/j.ijpharm.2005.08.008
M. J. Heffernan N. Murthy (2005)ArticleTitlePolyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicleBioconjug. Chem.16 1340–1342OccurrenceHandle16287226OccurrenceHandle1:CAS:528:DC%2BD2MXhtVKhtr7JOccurrenceHandle10.1021/bc050176w
S. A. Galindo-Rodriguez F. Puel S. Briancon E. Allemann E. Doelker H. Fessi (2005)ArticleTitleComparative scale-up of three methods for producing ibuprofen-loaded nanoparticlesEur. J. Pharm. Sci.25 357–367OccurrenceHandle15916889OccurrenceHandle1:CAS:528:DC%2BD2MXlsVCltLk%3DOccurrenceHandle10.1016/j.ejps.2005.03.013
E. Merisko-Liversidge G. G. Liversidge E. R. Cooper (2003)ArticleTitleNanosizing: a formulation approach for poorly-water-soluble compoundsEur. J. Pharm. Sci.18 113–120OccurrenceHandle12594003OccurrenceHandle1:CAS:528:DC%2BD3sXht1Kltrg%3DOccurrenceHandle10.1016/S0928-0987(02)00251-8
N. Rasenak H. Hartenhauer B. W. Muller (2003)ArticleTitleMicrocrystals for dissolution rate enhancement of poorly water-soluble drugsInt. J. Pharm.254 137–145OccurrenceHandle10.1016/S0378-5173(03)00005-XOccurrenceHandle1:CAS:528:DC%2BD3sXhsFOrtb8%3D
A. Eidelman J. M. Weiss J. Lau D. B. Carr (2005)ArticleTitleTopical anaesthetics for dermal instrumentation: a systematic review of randomized, controlled trialsAnn. Emerg. Med.46 343–351OccurrenceHandle16187468OccurrenceHandle10.1016/j.annemergmed.2005.01.028
A. Taddio H. K. Soin S. Schuh G. Koren D. Scolnik (2005)ArticleTitleLiposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trialCMAJ172 1691–1695OccurrenceHandle15967972
E. R. Viscusi (2004)ArticleTitleEmerging techniques in the treatment of postoperative painAm. J. Health-Syst. Pharm.61IssueID (Suppl 1) S11–S14OccurrenceHandle15119756
E. R. Vuscusi G. Martin C. T. Hartrick N. Singla G. ManvelianInstitutionalAuthorNameThe EREM Study group (2005)ArticleTitleForty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulationAnesthesiology102 1014–1022OccurrenceHandle10.1097/00000542-200505000-00022
S. A. Grant (2002)ArticleTitleThe holy grail: long acting local anaesthetics and liposomesBest Pract. Res. Clin. Anaesthesiol.16 345–352OccurrenceHandle12491562OccurrenceHandle1:CAS:528:DC%2BD38XntVygtL0%3DOccurrenceHandle10.1053/bean.2002.0242
S. Mantripragada (2002)ArticleTitleA lipid based depot (DepoFoam technology) for sustained release drug deliveryProg. Lipid Res.41 392–406OccurrenceHandle12121719OccurrenceHandle1:CAS:528:DC%2BD38Xltleku7g%3DOccurrenceHandle10.1016/S0163-7827(02)00004-8
A. Lamprecht J. L. Saumet J. Roux J. P. Benoit (2004)ArticleTitleLipid nanocarriers as drug delivery system for ibuprofen in pain treatmentInt. J. Pharm.278 407–414OccurrenceHandle15196644OccurrenceHandle1:CAS:528:DC%2BD2cXkslKlsrk%3DOccurrenceHandle10.1016/j.ijpharm.2004.03.018
D. Betbeder S. Sperandio J. P. Latapie J. NadaiParticleDe A. Etienn J. M. Zajac B. Frances (2000)ArticleTitleBiovector™ nanoparticles improve antinociceptive efficacy of nasal morphinePharm. Res.17 743–748OccurrenceHandle10955851OccurrenceHandle1:CAS:528:DC%2BD3cXlvVCgt78%3DOccurrenceHandle10.1023/A:1007594602449
A. M. Wolka J. D. Huber T. P. Davis (2003)ArticleTitlePain and the blood–brain barrier: obstacles to drug deliveryAdv. Drug Deliv. Rev.55 987–1006OccurrenceHandle12935941OccurrenceHandle1:CAS:528:DC%2BD3sXmsVKisbY%3DOccurrenceHandle10.1016/S0169-409X(03)00100-5
W. M. Pardridge (1999)ArticleTitleVector-mediated drug delivery to the brainAdv. Drug Deliv. Rev.36 299–321OccurrenceHandle10837722OccurrenceHandle1:CAS:528:DyaK1MXhvVCnsrs%3DOccurrenceHandle10.1016/S0169-409X(98)00087-8
J. C. Olivier (2005)ArticleTitleDrug transport to brain with targeted nanoparticlesNeuroRx2 108–119OccurrenceHandle15717062OccurrenceHandle10.1602/neurorx.2.1.108
W. M. Pardridge (2005)ArticleTitleDrug and gene targeting to the brain via blood–brain barrier receptor-mediated transport systemsInt. Congr. Ser.1277 49–62OccurrenceHandle10.1016/j.ics.2005.02.011OccurrenceHandle1:CAS:528:DC%2BD1cXhvVOhtb0%3D
J. Kreuter (2004)ArticleTitleInfluence of the surface properties on nanoparticle-mediated transport of drugs to the brainJ. Nanosci. Nanotechnol.4 484–488OccurrenceHandle15503433OccurrenceHandle1:CAS:528:DC%2BD2cXotVegur0%3DOccurrenceHandle10.1166/jnn.2003.077
M. Brandl G. Gregoriadis (1994)ArticleTitleEntrapment of haemoglobin into liposomes by the dehydration–rehydration method: vesicle characterization andin vivo behaviourBiochim. Biophys. Acta1196 65–75OccurrenceHandle7986812OccurrenceHandle1:CAS:528:DyaK2MXisFaktLs%3DOccurrenceHandle10.1016/0005-2736(94)90296-8
H. Sakai H. Y. Masada Horinouchi E. Ikeda K. Sou S. Takeoka M. Suematsu M. Takaori K. Kobayashi E. Tsuchida (2004)ArticleTitlePhysiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 daysJ. Pharmacol. Exp. Ther.311 874–884OccurrenceHandle15297471OccurrenceHandle1:CAS:528:DC%2BD2cXhtVKmt7fFOccurrenceHandle10.1124/jpet.104.073049
M. Takaori (2005)ArticleTitleApproach to clinical trial considering medical ethics and efficacy for HbV, liposome encapsulated hemoglobin vesicleArtif. Cells Blood Substit. Immobil. Biotechnol.33 65–73OccurrenceHandle15768566OccurrenceHandle1:CAS:528:DC%2BD2MXislOjsr0%3D
T. M. S. Chang F. D'Agnillo W. P. Yu S. Razack (2000)ArticleTitleTwo future generations of blood substitutes based on polyhemoglobin–SOD–catalase and nanoencapsulationAdv. Drug Deliv. Rev.40 213–218OccurrenceHandle10837791OccurrenceHandle1:CAS:528:DC%2BD3cXosVahuw%3D%3DOccurrenceHandle10.1016/S0169-409X(99)00051-4
A. J. Khopade S. Khopade N. K. Jain (2002)ArticleTitleDevelopment of hemoglobin aquasomes from spherical hydroxyapatite cores precipitated in the presence of half-generation poly(amidoamine) dendrimerInt. J. Pharm.241 145–154OccurrenceHandle12086730OccurrenceHandle1:CAS:528:DC%2BD38XkslSgs7w%3DOccurrenceHandle10.1016/S0378-5173(02)00235-1
C. Chauvierre M. C. Marden C. Vauthier D. Labarre P. Couvreur L. Leclerc (2004)ArticleTitleHeparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrierBiomaterials25 3081–3086OccurrenceHandle14967542OccurrenceHandle1:CAS:528:DC%2BD2cXhtVemtrk%3DOccurrenceHandle10.1016/j.biomaterials.2003.09.097
T. M. Chang D. Powanda W. P. Yu (2003)ArticleTitleAnalysis of polyethylene–glycol–polylactide nano-dimension artificial red blood cells maintaining systemic hemoglobin levels and prevention of methemoglobin formationArtif. Cells Blood Substit. Immobil. Biotechnol.31 231–247OccurrenceHandle12906306OccurrenceHandle1:CAS:528:DC%2BD3sXlsFKjurc%3DOccurrenceHandle10.1081/BIO-120023155
H. Sakai Y. Masada H. Onuma S. Takeoka E. Tsuchida (2004)ArticleTitleReduction of methemoglobin via electron transfer from photoreduced flavin: restoration of O2-binding of concentrated hemoglobin solution coencapsulated in phospholipid vesiclesBioconjug. Chem.15 1037–1045OccurrenceHandle15366957OccurrenceHandle1:CAS:528:DC%2BD2cXmvFChsrk%3DOccurrenceHandle10.1021/bc049913z
C. Passirani G. Barratt J. P. Devissageut D. Labarre (1998)ArticleTitleLong-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate)Pharm. Res.15 1046–1050OccurrenceHandle9688058OccurrenceHandle1:CAS:528:DyaK1cXkvVWgtbc%3DOccurrenceHandle10.1023/A:1011930127562
T. Flynn C. Wei (2005)ArticleTitleThe pathway to commercialization for nanomedicineNanomed. Nanotechnol., Biol. Med.1 47–51OccurrenceHandle1:CAS:528:DC%2BD2MXlvVSru74%3DOccurrenceHandle10.1016/j.nano.2004.11.010
B. Sangro (2005)ArticleTitleRefined tools for the treatment of hepatocellular carcinomaJ. Hepatol.42 629–631OccurrenceHandle15826709OccurrenceHandle10.1016/j.jhep.2005.02.006
C. H. Dubin. Drug discovery and delivery: tear down those walls. Drug Delivery Technology. 3#5 (2005).http://www.drugdeliverytech.com/cgi-bin/article.cgi?idArticle=329 (accessed 08/09/2005), part ofhttp://www.drugdeliverytech.com (accessed 08/09/2005).
C. L. Bennett E. A. Calhoun (2004)ArticleTitlePharmacoeconomics of liposomal anthracycline therapySemin. Oncol.31 191–195OccurrenceHandle15717744OccurrenceHandle1:CAS:528:DC%2BD2MXhtVynsLs%3DOccurrenceHandle10.1053/j.seminoncol.2004.08.008
F. J. Martin and T. Huang. Stealth liposomal technology: current therapies and future directions. Drug Delivery Technology. 3#5 (2005).http://www.drugdeliverytech.com/cgi-bin/article.cgi?idArticle=155 (accessed 08/09/2005), part ofhttp://www.drugdeliverytech.com (accessed 08/09/2005).
http://ClinicalTrials.gov/ct/gui/action/GetStudy (accessed 12/09/2005) part ofhttp://ClinicalTrials.gov (accessed 12/09/2005).
Z. Galanbor S. A. Marashi B. Rajbar (2005)ArticleTitleNanotechnology helps medicine: nanoscale swimmers and their future applicationsMed. Hypotheses65 198–199OccurrenceHandle10.1016/j.mehy.2005.01.023
A. Cavalcanti R. A. Freitas (2005)ArticleTitleNanorobotics control design: a collective behavior approach for medicineIEEE Trans. Nanobiosci.4 133–140OccurrenceHandle10.1109/TNB.2005.850469
T. Kubik K. Bogunia-Kubik M. Sugisaka (2005)ArticleTitleNanotechnology on duty in medical applicationsCurr. Pharm. Biotechnol.6 17–33OccurrenceHandle15727553OccurrenceHandle1:CAS:528:DC%2BD2MXhsVWqtbY%3D
M. D. Burke. Drug delivery technology assessment: the eight assessment gates. Drug Delivery Technology. 3#5 (2005).http://www.drugdeliverytech.com/cgi-bin/article.cgi?idArticle=343 (accessed 08/09/2005), part ofhttp://www.drugdeliverytech.com (accessed 08/09/2005).
B. Bastani D. Fernandez (2002)ArticleTitleIntellectual property rights in nanotechnologyThin Solid Films420–421 472–477OccurrenceHandle10.1016/S0040-6090(02)00843-X
N. Sadrieh. FDA perspective on nanomaterial containing products. Nanobusiness Conference May 2005.http://www.fda.gov/nanotechnology/powerpoint_conversions/May05_files/handout/index.html (accessed 6 September 2005), part ofhttp://www.fda.gov (accessed 6 September 2005).
Nanotechnologies: A Preliminary Risk Analysis on the Basis of a Workshop Organized by the Health and Consumer Protection Directorate General of the European Commission. European Community 2004.http://europa.eu.int/comm/health/ph_risk/events_risk_en.htm (accessed 22 December 2005), part ofhttp://europa.eu.int (accessed 22 December 2005).
P. J. Borm W. Kreyling (2004)ArticleTitleToxicological hazards of inhaled nanoparticles—potential implications for drug deliveryJ. Nanosci. Nanotechnol.4 521–531OccurrenceHandle15503438OccurrenceHandle1:CAS:528:DC%2BD2cXotVegurY%3DOccurrenceHandle10.1166/jnn.2004.081
Author information
Authors and Affiliations
Laboratoire de Physico-chimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, Université de Paris Sud, 5 Rue J.B. Clément, 92 296, Chatenay-Malabry Cedex, France
Patrick Couvreur & Christine Vauthier
- Patrick Couvreur
Search author on:PubMed Google Scholar
- Christine Vauthier
Search author on:PubMed Google Scholar
Corresponding author
Correspondence toChristine Vauthier.
Rights and permissions
About this article
Cite this article
Couvreur, P., Vauthier, C. Nanotechnology: Intelligent Design to Treat Complex Disease.Pharm Res23, 1417–1450 (2006). https://doi.org/10.1007/s11095-006-0284-8
Received:
Accepted:
Published:
Issue date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative